NZ609219B2 - Anticancer fusion protein - Google Patents
Anticancer fusion protein Download PDFInfo
- Publication number
- NZ609219B2 NZ609219B2 NZ609219A NZ60921912A NZ609219B2 NZ 609219 B2 NZ609219 B2 NZ 609219B2 NZ 609219 A NZ609219 A NZ 609219A NZ 60921912 A NZ60921912 A NZ 60921912A NZ 609219 B2 NZ609219 B2 NZ 609219B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- sequence
- fusion protein
- mean
- domain
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 216
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 215
- 230000001093 anti-cancer Effects 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 122
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 119
- 239000012634 fragment Substances 0.000 claims abstract description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 96
- 150000001413 amino acids Chemical class 0.000 claims abstract description 50
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 24
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 239000003102 growth factor Substances 0.000 claims abstract description 11
- 102000009465 Growth Factor Receptors Human genes 0.000 claims abstract description 9
- 108010009202 Growth Factor Receptors Proteins 0.000 claims abstract description 9
- 235000018102 proteins Nutrition 0.000 claims description 111
- 235000001014 amino acid Nutrition 0.000 claims description 49
- 238000003776 cleavage reaction Methods 0.000 claims description 34
- 230000007017 scission Effects 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 27
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101150007028 HTRA1 gene Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 abstract description 72
- 230000001772 anti-angiogenic effect Effects 0.000 abstract description 23
- 206010028980 Neoplasm Diseases 0.000 description 138
- 210000004027 cell Anatomy 0.000 description 138
- 241000699670 Mus sp. Species 0.000 description 89
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 67
- 108700012411 TNFSF10 Proteins 0.000 description 67
- 238000000034 method Methods 0.000 description 62
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 59
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 46
- 201000011510 cancer Diseases 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 238000011282 treatment Methods 0.000 description 32
- 230000004927 fusion Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 230000005764 inhibitory process Effects 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 29
- 108091026890 Coding region Proteins 0.000 description 28
- 230000004614 tumor growth Effects 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- 229930182555 Penicillin Natural products 0.000 description 26
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 26
- 229940049954 penicillin Drugs 0.000 description 26
- 230000002018 overexpression Effects 0.000 description 24
- 229960005322 streptomycin Drugs 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 20
- 239000000872 buffer Substances 0.000 description 20
- 201000005202 lung cancer Diseases 0.000 description 20
- 208000020816 lung neoplasm Diseases 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 17
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 17
- 239000012981 Hank's balanced salt solution Substances 0.000 description 16
- 108090000190 Thrombin Proteins 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 229960004072 thrombin Drugs 0.000 description 16
- 102100022749 Aminopeptidase N Human genes 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 14
- 208000029742 colonic neoplasm Diseases 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 14
- 230000009036 growth inhibition Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 102400000731 Tumstatin Human genes 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 210000000278 spinal cord Anatomy 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 230000004565 tumor cell growth Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 9
- 239000012537 formulation buffer Substances 0.000 description 9
- 108010049990 CD13 Antigens Proteins 0.000 description 8
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100020870 La-related protein 6 Human genes 0.000 description 7
- 108050008265 La-related protein 6 Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 7
- 238000002983 circular dichroism Methods 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000011592 zinc chloride Substances 0.000 description 7
- 235000005074 zinc chloride Nutrition 0.000 description 7
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 7
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 235000013681 dietary sucrose Nutrition 0.000 description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 description 6
- 235000019800 disodium phosphate Nutrition 0.000 description 6
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 101100042683 Arabidopsis thaliana SLAC1 gene Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100031186 Chromogranin-A Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000922140 Drosophila melanogaster Peripheral plasma membrane protein CASK Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000037965 uterine sarcoma Diseases 0.000 description 4
- 108010060757 vasostatin Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010049207 Death Domain Receptors Proteins 0.000 description 3
- 102000009058 Death Domain Receptors Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108091008611 Protein Kinase B Proteins 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000549 Calreticulin Proteins 0.000 description 2
- 102000004082 Calreticulin Human genes 0.000 description 2
- 102400000730 Canstatin Human genes 0.000 description 2
- 101800000626 Canstatin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NSTUFLGQJCOCDL-UWVGGRQHSA-N Gly-Leu-Arg Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NSTUFLGQJCOCDL-UWVGGRQHSA-N 0.000 description 2
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 108010077861 Kininogens Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012152 bradford reagent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 102000044949 human TNFSF10 Human genes 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 241000501458 Cultus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- XTDALQSFSCVEQQ-UHFFFAOYSA-N Mama 5 Natural products C=1C=CC=CC=1C(=O)OC1C2(C)C(OC(=O)C=3C=CC=CC=3)C(OC(=O)C)C(OC(C)=O)C(C)(O)C2(OC2(C)C)CC2C1OC(=O)C1=CC=CC=C1 XTDALQSFSCVEQQ-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001108995 Messa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- 108091008003 TRAIL-RI Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 101100221226 Zea mays COAC2 gene Proteins 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006481 angiogenic pathway Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- OQUUTERJWTYTHP-UHFFFAOYSA-N butanedioate;1h-tetrazol-1-ium Chemical compound [NH2+]1C=NN=N1.[NH2+]1C=NN=N1.[O-]C(=O)CCC([O-])=O OQUUTERJWTYTHP-UHFFFAOYSA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010083551 iturelix Proteins 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Abstract
Disclosed is a fusion protein comprising: domain (a) comprising a functional fragment of soluble hTRAIL protein sequence starting with amino acid in a position not lower than hTRAIL95 or a sequence having at least 70% sequence identity with said functional fragment; and domain (b) constituting a sequence of anti-angiogenic effector peptide which is the inhibitor of growth factor receptor and is selected from the group of growth factor fragments consisting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ. No. 22 and EGF fragment of SEQ. No. 23; the sequences as disclosed in the specification; wherein the sequence of domain (b) is attached at C - terminus or N - terminus of domain (a). a sequence of anti-angiogenic effector peptide which is the inhibitor of growth factor receptor and is selected from the group of growth factor fragments consisting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ. No. 22 and EGF fragment of SEQ. No. 23; the sequences as disclosed in the specification; wherein the sequence of domain (b) is attached at C - terminus or N - terminus of domain (a).
Description
Anticancer fusion n
The ion relates to the field of therapeutic fusion proteins, in particular
recombinant fusion proteins. More particularly, the invention relates to fusion
proteins containing the fragment of a ce of the soluble human TRAIL
protein in combination with a sequence of an antiangiogenic peptide,
pharmaceutical compositions containing them, their use in therapy,
particularly as anticancer agents, and to polynucleotide ces encoding
the fusion proteins, sion vectors containing the potynucleotide
sequences, and host cells containing these expression vectors.
TRAIL protein belonging to the cytokines family (Tumor Necrosis Factor-
Related sis Inducing Ligand), also known as Apo2L (Apo2-Ugand), is a
potent activator of apoptosis in tumor cells and in cells infected by viruses.
TRAIL is a Ugand naturally occurring in the body. TRAIL protein, its amino acid
sequence, coding DNA sequences and n expression systems were disclosed
for the first time in EP0835305A1.
TRAIL protein exerts its anticancer activity by binding to pro-apoptotic TRAIL
surface receptors 1 and 2 (TRAIL-RI /R2) and subsequent activation of these
Which acts on Wide
I" ‘
range Ofd1fferent types 'Of tumor-cells,1nclud1ng hematologic mal1gnanc1es and?" .‘
solid tumors, while sparing normal cells and exerting potentially relat1vely_$1_v'___'
small side effects
TRAIL protein is a type ”III membrane protein having the length of281 amino
acids, and its ellular region comprising amino acid residues 114-281 upon -
cleavage by ses forms soluble sTRAIL molecule of 20 kDa size, which is
also biologically active. Both TRAIL and sTRAIL forms are capable of triggering
apoptosis via interaction with TRAIL receptors present on target cells. Strong
antitumour activity and very low systemic toxicity of soluble part 'of TRAIL
'1' ‘
-.
_ moleculeWas demonstrated Using cell lines tests
8' ”xi-Also, I
human cl1n1cal s W1th recombinant human soluble TRAIL (rhTRAIL):
1 ..
, ‘ammoac1ds 114-281 of} hTRAIL
, -i.hav1ng aminoac1dsequen”
' 7 ‘ showed
nder"the INNdulanermin 1ts. goo oleran'ceandabsence 0_
' "'2' ”dosel1m1t1ng tox1'c1ty3 " -'
._ .‘
death receptors and induceapoptos1s Via these recep 11,;Ta's recentlyrep: .,
for recomb1nantc1rcularlypermuted mutant Of 122-" 1'hTRAIL for exampleinfi- '1.
"EP1 688498 --
‘ -
lTOxic effects '
'of inant TRAIL n on liver cells repartedup to V-f‘ -_
appear to be assoc1ated w1th the pres neeof mod1f1cat1on iepolyhistidmei'; '
‘ ‘
n tags, wh1 le untagged TRAILshowed no systemic tox1c1ty~.
resistance of tumors to TRAIL, various combination therapies with radio- and
chemotherapeutic agents were designed, which resulted in synergistic
s apoptotic effect (W02009/002947; A. Almasan and A Ashkenazi, tytokine
Growth Factor Reviews 14 (2003) 337-348; Rk Srivastava, Neoptasis, Vol 3, No
6, 2001, 535-546, Soria JC et at., J. Clin. Oncology, Vol 28, No 9 , p.
1527-1533). The use of rhTRAIL for cancer treatment in ation with
selected conventional chemotherapeutic agents (pactitaxel, carboptatin) and
monoclonal anti-VEGF dies are bed in W02009/140469. However,
such a combination necessarily implies well-known deficiencies of conventional
chemotherapy or radiotherapy.
Moreover, the problem connected with TRAIL y has proved to be its tow
stability and rapid ation from the body after administration.
One of the targets in cancer y is also the inhibition of tumor
angfogenesis AngiogenØsis asculàrisation) is a pathological, timeunlimited
process of developing new blood vessels that supply tumors with
oxygen and nts. Mgiogenesis is indispensable for the growth and
expansion of the tumor and ing its asis
Beneficial effect of inhibition of tumor angiogenesis incancer therapy is
known. Attempts were made to the clinical use of substances that inhibit or
regulate the process of angiogenesis, both as a cancer therapy and a
complementary cancer therapy.
Inhibitors of angiogenesis are known, both endogenous ones naturally present
in the human body and numerous exogenous antiangiogenic substances. Among
them there are known protelnaceous inhibitors of angiogenesis, including
proteolytic fragments of endogenous proteins As examples, the protein
inhibitors of angiogØnØsis such angiostatin (a fragment of nn),oge
endostatin (C terminal fragment of collagen XVIII), calreticulin, vasostatin a
catreticuUn fragment, a fragment Of pro act’ a fragment of metalloproteiriase
2, or tumstatin - a fragment of cOlLagen IV, can be mentioned (Cab Y.
Angiogenesis modulates adipogenesis and obesity J On Invest
2007;117(9):2362-2368, n J. Angiogenesis: an organizing principle for
drug discovery? at Rev Drug Discov. 2007;6:273-286).
For exampLe, tumstatin is a peptide of the size of 28 kDa - a fragment of
coLLagen type IV, capable o,. to in’tegrin avB3 and preventing
angiogenesis by inhibition of elial cells proliferation. Moreover,
tumstatin independently inhibits activation of Focal Adhesion Kinase (FAK) and
phosphatidytinositoL 3-kinase P13 and protein kinase PKB/Akt.
Antiangiogenic activity may be also exerted by inhibition of pro-angiogenic
proteins, such as Vascular Endothelial Growth Factor (VEGF), which acts
through receptors Located on vascular endothelium and which is the main
stimulator of neoangiogenesis.
In clinical treatment, including cancer therapy, have already been used as
antiangiogenic s certain nces ed against VEGF, such as
monoclonal antibodies bevadzumab and ranibizumab. Other proangiogenic
factors stimulating the proliferation and migration of endothelial cells
independently of receptors d on the endothelium are also known, which
include for example, cytokines such as et-Detived Growth Factors PDGF
and epidermaL growth factor EGF, TNF, and angiopoietin.
In the s of enesis there is also involved the enzyme
aminopeptidase N (APN/CDI3), which is a transmembrane metaLloprotease. It
is known that inhibition of this enzyme may lead to tion of neopLastic
processes. A number natural and synthetic inhibitors of aminopeptidase N are
known. (Bavouis B., Dauzonne D., Aminopeptidase-N/CD13 (EC 3.4.11.2)
inhibitors: chemistry, biological evaluations, and therapeutic prospects.
Medical Research Review, 2006, 26, (1), 88-130).
Natural Inhibitors of APN/CD13 incLude mainly substances ed by
rganisms. As an representative, among others bestatin, curcumin, and
apigenin may be mentioned. It was also found that a short peptide containing
CNGRC motif is able to efficiently bind to CD13 (Arap et at., Science, 279:377-
380, 1998).
Many of the antiangiogenic substances are currently at different stages of
investigations, including clinical trials. However, known therapies aimed at
inhibiting enesis have many well-known disadvantages. For example the,
benefits of therapeutic monoclonal antibody bevadzumab in the treatment of
breast cancer have been recently questioned. Many antiangiogenic drugs show,
for example, a very short half-life, low lity, poor bioavailability and toxic
side effects.
Safety of anti -angiogenic: drugs is of special importance because of prolonged
use and lack of selectivity of therapy. Strong need for an effective therapeutic
and the nature of oncological es necessitate a simplified registration
procedure for such group of drugs, therefore it is impossible to know all the
side effects and drawbacks of the drug. Although, contrary to the
chemiotherapeutics, which are directed to all fast proliferating cells,
antiangiogenic drugs are directed at different stages of the formation of blood
s, which results in reduction of the toxicity of therapy. However, there is
still a need of anticancer therapy which is aimed at inhibiting angiogenesis
while ensuring selectivity against tumor cells. There is therefore a need for
new antiangiogenic anticancer therapies with improved toxicological
characteristics.
Constructed fusion protein containing sequences of an angiogenesis tor
vasostatin and 14-281 linked with a metalloprotease cleavage site tinker
was described as exhibiting sis-indudæg effect in tumor cells by A. I. Guo
et at in Chinese Journal of Biochemistry. and lar y 2008, vol.
24(10), 925-930.
Constructed fusion protein containing sequences of an angiogenesis inhibitor
catreticulin and TRAIL1 14-281 was described as exhibiting apoptosis-inducing
effect in tumor cells in 124A.
CN 1256347C discloses fusion protein ed of kininogen D5 60-148 and
TRAIl 114 281
Constructed ’fusion n ning sequences of an angiogenesis inhibitor
kininostatin, vasostatin and canstatin attached to N- or C-terminus of
TRAILI14 281 linked with Linker encoding GGGSGGSG are mentioned In Feng
Feng-Yi "Phase and Clinical Trial of Rh-Apö2L and A002L.ReLated Experimental
Study", Ph.D. degree thesis, Chinese Peking Union Medical, 200601;
http / /www Lw23 corn / lunwen_957708432
ucted fusion protein containing sequences Tumstatin 183-230 of an:
domain It isstatedthatactivation 6quthe construct isvia binding6f_I IiIItIs CD
I IIIp‘azrt'r. _II IILI .‘ '5»
w ‘- .
The present ion provides a solijtion of this prdblem by providing” poi/en
i 10 fusion proteins that comprise a domain” derived from TRAIL and a short éiiectorfi‘
peptide domain having the antiangiogenic actiVity ‘and not including“ 'TRAIIL'I- I;
fragments, wherein the peptide potentiate‘s or complements the;
‘effeCtor
action of _
Proteins according to the invention Iar ed selectively to cancer cells.II'. a I'_I'_I‘
AdditionaLly, in many cases, novel fusion proteins also overcome resistance to
TRAIL.
Description of Figures
The invention will now be described in detail with reference to the Figures of
the drawing.
Fig. 1 presents a schematic ure of fusion proteins of the invention
according to Ex. 1, Ex. 2, Ex. 3, Ex. 4, Ex. 5 and Ex. 6..
Fig. 2 presents a schematic structure of fusion proteins of the invention
according to Ex. 7, Ex. 8 , Ex. 9, Ex. 10 and Ex. 11
Fig. 3 presents a schematic structure of fusion proteins of the invention
according to Ex. 12 , Ex. 13 , Ex. 141 Ex. 15.
Fig. 4 shows circular ism spectra for rhTRAIL95-281 and fusion proteins of
Ex. 1, Ex. 4Ex. 5, Ex. 9 and Ex. 14 expressed in specific ellipticity.
Fig. 5 presents tumor volume changes (% of l stage) in Crl:CDI-Foxnlnu
mice burdened with colon cancer HCTI 16 treated with fusion proteins of the
invention of Ex. 1, Ex. 4, Ex. 5 and Ex. 9 compared to rhTRAILII4-281
Fig. 6 presents the tumor growth inhibition values (%TGI) in Crl:CDI-Foxnl" I
mice burdened with colon cancer HCTII6 treated with fusion proteins of the
invention of z Ex 1, Ex 4, Ex 5 and Ex 9 compared to rhTRAILI14 281
Fig. 7 presents tumor volume changes (% of initial stage) in CrL:CD1-Foxnlflu
mice burdened with lung cancer A549 treated with fusion proteins of the
Invention of Lx. I compared to rhTRAILII4-281
Fig. 8 presents the tumor growth inhibition values (%TGI) in CrL:CD1-Foxh1 I
mice ed with lung cancer A549 treated with fusion proteins of the
invention of Ex. I compared to LII4-281.
Fig. 9 ts a schematic structure of fusion ns of the invention
according to Ex. 16, Ex. 17, Ex. 18 , and Ex. 19..
Fig. 10 presents tumor volume changes (% of initial stage) in CrL:CD1-Foxnlnu
mice ed with colon cancer HCTI 16 treated with fusion proteins of the
invention from Ex. 5. , Ex. 4. Ex. 9, and Ex. 1 compared to LI 14-281.
'1Fig;
12:.presents t .
3 Prkdc“““Hrhrm1ce burd’l" ’ed'w1th colon cancerHCT116 treatedw1th fu510n_ _"
' proteins of the 10n from Ex. 6 and Ex.11 compared to L114.
Fig. 13 presents the tumor growth inhibition values (96TGI).. in Crl:SHO-
Prkdcsc‘dHrhr mice burdened with colon “cancer HCT116 treated with fusic‘mw
proteins of the invention from Ex. 6 and Ex. 11 compared to rhTRAIL114-281.
Fig. 14 presents tumor volume changes (% of initial stage) in Crl.SHO-
Prkdc‘c‘dHrhr mice burdened with colon cancer Col0205 treated with fusion
proteins of the invention from Ex. 6 and Ex.19 compared to L114-281.
Fig. 15 presents the tumor growth inhibition values (%TGI) in Crlz-SHO
Prkdcsc‘dHrhr mice burdened with colOn cancer Col0205 treated with fusion _
151] p'rOteins of the invent10n from Ex. 6 and EX. 19compared to rhTRAIL114-281
".“Fi'g. 16 presents tumorvolume changes (96 of 1n1t1al stage)1n CrlSHo
‘Prkdcsc‘dHrh'miceburdi'fi'ed with coloncancer-_HW620‘ d withfu510n.";'-'l}'; .
I 7
.' "proteins of the 1nvent10nfrom'Ex 6 and Ex. 11compared. to L114281
F1g.17- presentsthe_' 'orfgrowth1nh1b1t10nvalues (%TGI) in CrlSHO _
= ' 20f 'Prkdcsc‘dHrh' m1ce burdened With colon cancer SW620 treated with fus10n-_=,.
proteins of the Invention from Ex. 6 and Ex. 11 ed to L114-281
Fig-.- 18 presents tumor volume s (96 6f 1n1t1al stagé) in beCg
f0xn1(nu)/J mice burdened WIth lung cancer A549 treated with fusion proteIn
of the inventidnfrdm Ex.1_compared to” rhTRAIL114-281
23* Fig. _ _
" foxn1(nu)/J m1ce burde'
Ofthe 1nvent10n from EX. 1 compared to rhTRAIL114281
F1g.i 20 presents tumor volume changes (96 of 1n1t1al stage) in CrlSHo
Prkdc‘“"‘Hrhr m1ce burdened With luhg cancér NCl-H460 treated with fus10n:
'30. protein of the 1nvent10n from Ex. 6 compared to rhTRAIL114281
Fig 21 presents the tumor, growth inhibition values (%TGI) in Cr1 SHO
Prkdecid Hrhe mice burdened with Lung cancer NCI H460 treated with fusion
protein of the invention from Ex 6 ed to rhTRAILII4 281
Fig 22 presents tumor volume changes (% of initial stage) in Cr1 SHO
S r’ mice burdened with lung cancer A549 treated with fusion protein
of the invention from Ex. 5, Ex. 6, Ex. 11 compared to rhTRAILII4-281.
Fig. 23 presents the tumor growth inhibition values (%TGI) in Cr(:SHOPrkdcsc
id mice burdened with lung cancer A549. treated with fusion protein
of the invention from Ex. 5, Ex. 6, Ex. 11 compared to rhTRAIL1I4-281.
Fig. 24 presents tumor volume changes (% of initial stage) in CrL:5HOPrkdc
H rI1I mice ed with lung cancer NCI-H460-Luc2 d with fusion
protein of the invention from Ex.5 compared to rhTRAILI .
Fig. 25 presents the tumor growth inhibition values (%TGI) in CrL:SHOPrkdcsHrhe
mice burdened with lung cancer NCI-H460-Luc2 treated with fusion
protein of the invention from Ex .5 compared to rhTRAILII4 281
Fig. 26 presents tumor volume changes (% of initial stage) in OP
rkdc iH rh1r mice burdened with lung cancer A549 treated with fusion proteins
of the invention from Ex 5 and Ex I compared to rhTRAIL114 281
Fig 27 presents the tumor growth inhibition values (%TGI) in Cr1 SHO
rkdcHr mice burdened with lung cancer A549 treated with fusion proteins
of the invention from Ex.5 and Ex.1 compared to LI14-281.
Fig. 28 presents tumor volume changes (% of initial stage) in Crl:SHOP
rkdcsH rhr mice burdened with liver cancer PLC/PRF/5 treated with fusion
Proteins of the invention from Ex. 6 and Ex. 11 compared to rhTRAIL1I4-281.
Fig 29 presents the tumor growth inhibition values (%TGI) in Cr1 SHO
scid mice burdened with liver cancer PLC/PRF/5 treated with fusion
proteins of the ion from Ex. 6 and Ex. 11 compared to rhTRAILII4-281.
Fig. 30 presents tumor volume changes (% of initial stage) in Crl:SHOP
rkdcsH rtI mice burdened with HepG2 Liver cancer d with fusion.
proteins of the invention from Ex 6 and Ex 19 compared to rhTRAILII4 281
Fig. 31 presents the tumor growth inhibition values (%TGI) in Crl:SHOP
rkdc5IH rh1r mice burdened with HepG2 Liver cancer treated with fusion
proteins of the invention from Ex. 6 and Ex. 19 compared to rhTRAIL1 14-281.
Fig. 32 presents tumor volume changes (% of initial stage) in Crl:SHOPrkdC5cid
Hrhr mice burdened with PANC-1 pancreas cancer d with fusion
protein of the invention from Ex. 11 compared to rhTRAI L1 14-281
Fig. 33 presents the tumor growth inhibition values (%TGI) in Crl:SHOPrkdcdHrhr
mice burdened with PANC-1 as cancer treated with fusion
n of the ion from Ex. 11 compared to rhTRAILII4-281.
Fig. 34 presents tumor volume changes (% of initial stage) in Crl:SHOPrkdcsH
rhht mice burdened with multidrug-resistant human uterine sarcoma
MES-SA/Dx5 treated with fusion proteins of the invention from Ex. 6 and Ex. 19
compared to rhTRAIL1I4-281.
Fig. 35 presents the tumor growth inhibition values (%TGI) in Crt:SHOPrkdCscid
hr mice burdened with rug- resistant human uterine sarcoma
MES-SA/Dx5 treated with fusion proteins of the invention from Ex. 6 and Ex. 19
compared to rhTRAILI14-281.
Detailed Description of the Invention
The invention relates to a fusion protein comprising:
- domain (a) which is the functional fragment of a sequence of soluble
hTRAIL protein, which fragment begins with an amino acid at a on
not lower than hTRAIL95 or a homolog of said functional fragment having
at least 70% sequence identity, and
- domain (b) which is a sequence of a giogenic effector peptide,
wherein the sequence of the domain (b) is attached at the C-terminus and/or
N-terminus of domain (a);
with the proviso that fusion ns are excluded wherein or peptide is
selected from the group consisting of calreticulin, tumstatin 183-230, kininogen
D5, vasostatin, kininostatin and canstatin.
According to one aspect the present invention s to a fusion protein
comprising: domain (a) sing a functional fragment of soluble hTRAIL
protein sequence starting with amino acid in a position not lower than hTRAIL95
or a sequence having at least 70% sequence ty with said functional fragment;
A1-126(864948 1_1):LNB
and domain (b) constituting a ce of anti-angiogenic effector e which is
the inhibitor of growth factor receptor and is selected from the group of growth
factor fragments consisting of VEGF fragment of SEQ. No. 17, PDGF nt of
SEQ. No. 22 and EGF fragment of SEQ. No. 23; wherein the sequence of domain
(b) is attached at C - terminus or N - terminus of domain (a).
According to another aspect the present invention relates to an isolated
polynucleotide sequence ng a fusion protein comprising: domain (a)
comprising a functional fragment of soluble hTRAIL n sequence starting
with amino acid in a position not lower than hTRAIL95 or a sequence having at
least 70% sequence identity with said functional fragment; and domain (b)
constituting a sequence of anti-angiogenic effector peptide which is the inhibitor of
growth factor receptor and is ed from the group of growth factor fragments
ting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ. No. 22 and
EGF fragment of SEQ. No. 23; wherein the sequence of domain (b) is attached at
C - terminus or N - terminus of domain (a).
According to another aspect the present invention relates to an expression vector
comprising a polynucleotide sequence encoding a fusion protein comprising:
domain (a) comprising a functional fragment of soluble hTRAIL protein sequence
starting with amino acid in a position not lower than hTRAIL95 or a sequence
having at least 70% sequence identity with said functional nt; and domain
(b) constituting a sequence of anti-angiogenic effector peptide which is the
inhibitor of growth factor receptor and is selected from the group of growth factor
fragments consisting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ.
No. 22 and EGF fragment of SEQ. No. 23; wherein the sequence of domain (b) is
attached at C - terminus or N - us of domain (a).
According to another aspect the present invention relates to a host cell comprising
an expression vector comprising a cleotide ce encoding a fusion
protein comprising: domain (a) comprising a onal fragment of soluble
hTRAIL protein sequence starting with amino acid in a position not lower than
95 or a sequence having at least 70% sequence identity with said
functional fragment; and domain (b) constituting a sequence of anti-angiogenic
A1-126(864948 1_1):LNB
1 Ob
effector e which is the inhibitor of growth factor receptor and is selected
from the group of growth factor fragments ting of VEGF nt of SEQ.
No. 17, PDGF fragment of SEQ. No. 22 and EGF fragment of SEQ. No. 23;
wherein the ce of domain (b) is attached at C - terminus or N - terminus of
domain (a).
According to r aspect the present ion relates to a pharmaceutical
ition comprising as an active ingredient a fusion n comprising:
domain (a) comprising a functional fragment of soluble 1iTRAJL n sequence
starting with amino acid in a position not lower than hTRAIL95 or a sequence
having at least 70% sequence identity with said functional fragment; and domain
(b) constituting a sequence of anti-angiogenic effector peptide which is the
inhibitor of growth factor receptor and is ed from the group of growth factor
fragments consisting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ.
No. 22 and EGF fragment of SEQ. No. 23; wherein the sequence of domain (b) is
attached at C - terminus or N - terminus of domain (a).
According to another aspect the present invention relates to a use of a fusion
protein comprising: domain (a) comprising a functional fragment of soluble
hTRAIL protein sequence starting with amino acid in a position not lower than
hTRAIL95 or a sequence having at least 70% sequence identity with said
functional fragment; and domain (b) constituting a sequence of anti-angiogenic
effector peptide which is the inhibitor of growth factor receptor and is selected
from the group of growth factor fragments consisting of VEGF fragment of SEQ.
No. 17, PDGF fragment of SEQ. No. 22 and EGF fragment of SEQ. No. 23;
wherein the sequence of domain (b) is attached at C - us or N - terminus of
domain (a) for the manufacture of a medicament for the treatment of neoplastic
diseases in mammals including humans.
The term "the functional soluble fragment of a sequence of soluble hTRAIL"
should be understood as denoting any such fragment of soluble hTRAIL that is
AH26(864948 1_1):LNB
capable: of inducing apoptotic signal in mammalian cells upon binding to its
ors on the surface of the cells.
It will be also iated by a skilled person that the existence of at least 70%
homology of the TRAIL sequence is known in the art
It should be understood that domain (b) of the effector peptide in the fusion
protein of the invention is neither hTRAIL protein nor a part or fragment of
hTRAIL protein.
The term "peptide" in accordance with the invention should be understood as a
molecule built from plurality of amino acids linked together by means of a
peptide bond. Thus, the term "peptide" according to the invention es
oligopeptides, polypeptides and proteins.
In the present ion the aminoacid sequences of peptides will be presented
in a conventional manner adopted in the art in the direction from N-terminus
) of the peptide s its C-terminus (C-end). Any sequence will thus
have its N-terminus on the left side and inus on the right side of its
linear presentation.
The fusion n of the invention incorporates at least one domain (b) of the
effector peptide, attached at the inus or N-terminus of domain (a).
In a particular embodiment, the domain (a) is a fragment of hTRAIL sequence,
beginning with an amino acid from the range of hTRAIL95 to hTRAILI2I,
inclusive, and ending with the amino acid hTRAIL 281.
In particular, domain (a) may be selected from the group consisting of
sequences corresponding to hTRAIL95-281, hTRAILI 19-281, hTRAILI20-281 and
hTRAIL12I-281. It will be evident tot hose skilled in the art that hTRAIL95281,
hTRAIL1 19-281, hTRAILI20-281. and hTRAILI21 -281 represent a fragment of
human TRAIL protein starting with amino acid marked with the number 95, 119,
120 and 121, respectively, in the known sequence of hTRAIL (SEQ. No. 16)
published in Gen Bank under Accession No P50591.
In another ular embodiment, the domain (a) is a homoLog of functional
fragment of soluble hTRAIL protein sequence beginning at amino acid position
not lower than hTRAIL95 and ending at amino acid hTRAIL28I, the sequence of
which is at Least in 70%, preferably in 85%, identical to original sequence.
In specific variants of this embodiment the domain (a) is a homolog of a
nt selected from the group consisting of ces corresponding to
hTRAIL95 281, II4 281, hTRAILII6 281, hTRAILI20 281, MAIL! 21.291
and hTRAILI22 281
It should be understood that a homolog of a hTRAIL fragment is a
variation /modification of the amino acid sequenced this fragment, wherein at,
Least one amino acid is changed, including I amino acid, 2 amino acids, 3
amino acids, 4 amino acids, 5 amino acids, 6 amino acids, and not more than
% of amino acids, and wherein a fragment of the ed ce has
preserved functionality of the hTRAIL sequence, i.e. the ability of binding to
cell surface death receptors and inducing apoptosis In mammalian cells.
Modification of the amino acid sequence may include, for example,
substitution, deletion and/or addition of amino acids.
Preferably, the g of hTRAIL fragment having ed sequence shows a
ed affinity to the death receptors DR4 (TRAIL RI) or DR5 (TRAIL R2) in
comparison with the native fragment of hTRAIL
The term modified affinity refers to an increased affinity and/or affinity with
altered receptor selectivity
Preferably, the homolog of the fragment of hTRAIL having modified seque nce
shows increased affinity to the death receptors DR4 and DR5 compared to
native fragment of hTRAIL
Particularly preferably, the homoLog of fragment of IiTRAIL having ed
sequence shows increased affinity to the death receptor DR5 in coniparisoh i.
with the death receptor DR4, i.e. an increased selectivity 1)115/DR4
Also ably, the homolog of fragment of hTRAIL having modified sequence
shows an increased selectivity towards the death receptors DR4 and/or DR5 in
relation to the affinity towards the receptors DR1 (TRAIL-113) and/or DR2:
(TRAIL-R4).
Modifications of hTRAIL resuLting in increased affinity and selectivity
towards the death receptors DR4 and DR5 are known to those skilled in the art,
for example from the publication Tur V, van der Sloot AM, Reis CR, Szegezdi E,
Coot RH, Samali A, Serrano L, Quax WJ. elective tumor necrosis factorrelated
sis-indUcing Ugnd (TRAIL) variants obtained by structure-based
design. J. Biol. Chem. 2008 Jul 18;283(29):20560-8, which describes the D218H
mutation having increased selectivity towards DR4, or Gasparian ME, Chernyak
BY, Dolgikh DA, Yagolovich AY, Popova EN, a AM, vskii SA,
Kirpichntkov MP. Generation of new TRAIL mutants DR5-A and DR5-B with
improved selectivity to death receptor 5, Apoptosis. 2009 Jun;14(6):778-87,
which describes the D269H mutation having a reduced affinity towards DR4.
hTRAIL mutants resulting in sed affinity towards one receptor selected
from the DR4 and DR5 comparing with DRI and DR2 receptors and increased
affinity towards the receptor DR5 comparing with DR4 are also described in
W02009077857 and W02009066174.
is Suitable mutations are one or more mutations in the ons of native hTRAL
selected from the group consisting of 131, 149, 159, 193, 199, 201, 204, 204,
212 1 215, 218 and 251, in particular, mutations involving the substitution of an
amino acid with a basic amino acid such as lysine, histidine or arginine, or
amino add such as glutamic acid or ic acid. Particularly one or more
mutations selected from the group consisting of GI3IR, GI3IK, R1491, R149M,
R149N, R149K, S159R, Q193H, Q193K, N199H, N199R, K20IH, K201R, K204E,
K204D, K204L, K204Y, K212R, S215E, S215H, 5215K, , D218Y, D218H,
K251D, K251 and K251 Q, as bed in W02009066174, may be specified.
Suitable mutations are also one or more mutations In the positions of native
hTRAL selected from the group consisting of 195, 269 and 214, particularly
mutations involving the substitution of an amino acid with a basic amino acid
such as lysine, histidine or arginine. Particularly one or more mutations
selected from the group consisting of D269H, E195R, and T214R, as described in
W02009077857, may be specified.
In a particular ment, the domain (a) which is a homotog of the fragment
of hTRAIL is selected from D21 8H mutant of the native TRAIL sequence, as
described in 066174, or the Yl 89N-R1 91 K-Q1 93R-H264R-1266R- D269H
'- 1n(b) may be in particular selected from the followmg group
1:" - 1nh1b1tors 6f receptorsfor growth s selected from receptors for VEGF I; i
“- tumstatm 6r fragments thereof other than fragment 183230 and
- inhibitors of am1nopept1dase N (CD13).-. - ‘. i'
'10 Within the grbup of inhibitors of” receptors foragrowt—h'factors the effector
peptide of domain (b) may be a fragment of human vascular endothelial grOWth .
factor VEGF which binds the VEGF or competitively to the natural ligand
while being itself devoid of angiogenic activity As a consequence, ang1ogen1cf -_
act1v1tyofVEGF is blocked there 1s_ no:st1mulat1on of newi'bloo
invention will effectively eliminate cancer cells by inhibition of angiogenesis
process.
Also within the group of inhibitors of receptors for growth s, the
antiangiogehic effector peptide of domain (b) maybe a peptide fragment of
s Epidermal Growth Factor EGF, which binds the EGF receptor itively to
the natural ligand while being itself devoid of angiogenic activity. As a
consequence, angiogenic activity of EGF is blocked, there is no ation of
new blood s formation and tumor growth is inhibited. Such blocking
peptides Gly Leu Arg Ser Leu Lys Glu and Gly Leu Arg Ser Leu Arg Glu capable
to bind to EGF or without activation of ellular kinase and to block
EGR activity are known for example from EP0641358. In particular, such an
effector peptide- a fragment of EGF ligand, is shown by a sequence of SEQ.
No.23 in the attached Sequence Listing.
It is believed that the peptide comprising sequence of Epidermal Growth Factor
EGF incorporated into the fusion protein of the invention will ively
eliminate cancer cells by inhibition of angiogenesis process.
Within the group of tumstatin and its fragments the effector peptide of domain
(b) may be a 25-amino acid fragment of tumstatin protein (fragment I), shown
by the sequence of SEQ. No.18 In the attached Sequence Listing. The effector
peptide of the above presented group is also another 18-amino acids fragment
of tumstatin protein (fragment II), shown by a sequence of SEQ. No.19 in the
attached Sequence Listing. The antiangiogenic effector peptide of domain (b)
may be also a combination of tumstatin peptide nts, in particular
fragment and fragment II Located next to each other in any order. In one
embodiment, the domain (b) is a combination of nt I/fragment II (SEQ.
No 18/SEQ. No. 19) or a combination of fragment II/fragment I
(SEQ. No 19/SEQ. No. 18).
It is ed that the peptide comprising sequence of tumstatin n
fragment I and/or II incorporated into the fusion protein of the invention will
effectively eliminate cancer cells by inhibition of angiogenesis s.
The group of inhibitors of the aminopeptidase N/CDI3, which bind with enzyme
aminopeptidase N/CDI3 to inhibit its ty will include short peptides
containing motifs NGR or RGD.
Peptides inctüdihg motives NGR that bind efficiently to aminopØptidase N are
described for example by Arap et at., Science, 279:377-380, 1998. On the
extraceLlular domain of aminopeptidase N a fragment exhibiting affinity to RGD
motif is also present. Both motifs (RGD and NGR) bind as antagonists With
S factors involved in the process of neovascutarization. Therefore, it is likely that
RGD motif resembling NGR motif will bind with aminopeptidasØ N and consequently
act as its inhibitor (Friedlander et at. Definition of two angiogenic
pathways by distinct av integrins. Science (Washington DC), 270: 502,
1995; Pasquatini et at Aminopeptidase N is a receptor for tumor-homing
peptides and a target for inhibiting angiogenesis. Cancer Res. 2000 Feb
1;60(3):722-7).
Within the group of tors of the aminopeptidase , the
antiangiogenic effector peptide of domain (b) may be a 5-amino acid peptide
binding to CDI3 shown by SEQ. No. 20 in the attached ce Listing. Another
effector peptide of this group is also 9-amino acids peptide binding to CDI 3,
shown by SEQ. No.21 in the attached Sequence Listing.
It is ed that the peptide comprising sequence of the n fragment
binding with aminopeptidase N/CDI 3 incorporated into the fusion protein of
the invention will effectively eliminate cancer cells by inhibition of angiOge
Ii] nesis process.
The fusion proteins of the invention may comprise more than one effector
peptide domain (b), in particular two or three domains (b). In one embodiment
the fusion protein of the present invention contains two similar or different
effector domains (b) selected from SEQ. No. 17, SEQ. No. 18, SEQ. No. 19, SEQ.
No.20, SEQ. No.21, SEQ. No.22 and SEQ. No.23, wherein the or domains
(b) are Located next to each other. In other ment the fusion protein of
the present invention contains two similar or ent effector domains (b)
selected from SEQ. NO. 17, SEQ. No. 18, SEQ. No. 19, SEQ. No.20, SEQ. N0.21,
SEQ. No.22 and SEQ. No.23, n the or domains (b) are located at
the N-terminus and/or C-terminus of domain (a).
In particular embodiment the fusion protein of the present invention comprises
three effector domains.
As an e, the fusion protein comprises the peptide derived from VEGF
(SEQ. No. 17) d at the N-terminus of domain (a) and at the C-terminus Of.
domain (a) Located next to each other fragment I of tumstatin (SEQ. No. 18)
and nt II of tumstatin (SEQ. No. 19).
In specific embodiments of the fusion protein of the invention, the effector
peptide is a peptide having antiangiogenic activity seLected from the group
ting of SEQ. No. 17 (heptapeptide d from VEGF), SEQ. No. 18 (a
fragment I (amlnoadds 74-98) of tumstatin protein), SEQ. No. 19 (a fragment II
(aminoacids 4) of tumstatin protein), SEQ. No.20 (a peptide binding to
CD13), SEQ. No.21 (a peptide binding to CDI3), SEQ. No.22 (a fragment of
PDGF) and SEQ. No.23 (a fragment of EGF).
Upon binding to TRAIL receptors present on the surface of cancer cells, the
fusion protein will exert a double effect. Domain (a), that is a functional
fragment of TRAIL or its homolog with preserved functionality, will exert its
known agonistic activity - i.e. binding to death receptors on the cell surface
and activation of the extrinsic pathway of apoptosis. After internalization of
the fusion protein comprising antiangiogenic peptide, the domain (b) will be
able to potentially exert its action intracellularly in parallel to the activity of
TRAIL domain. In this way, anti-cancer activity of TRAIL can be potentiated by
activation of other elements and mechanisms -such as steric tion of
g site of the natural VEGF, PDGF and EGF Ligands, inhibition of
angiogenesis and neovascularisation, inhibition of activation of
phosphatidylinositot 3-kinase, protein kinase B kt) or indirect stimulation
of TRAIl overexpression by kinase Akt and NFk pathway.
In one of the embodiments of the invention, domain (a) and domain (b) are
linked by at Least one domain (c) comprising the sequence of a ge site
recognized by proteases present in the cell environment, especially in the
tumor cell environment. The linkage of the domain (a) with the domain (b) by
at least one domain (c) means that between domains (a) and (b) more than one
domain (c) may be t, in particular one or two s (c).
A protease cleavage site can be selected from:
- a sequence recognized by metalLoprotease MMP, in particular (Pro Leu Gly
Leu Ala Gly Glu Pro/PLGLAGEP) designated as SEQ. No.24, or (Pro Leu Gly lIe
Ala Gly Glu /PLGIAGE) ated as SEQ. No.55, or (Pro Leu Gly Leu Ala Gly
GluPro /PLGLAGEP) designated as SEQ. No. 56;
ation-lof; the- sequence recogmzed by metalloproteaseMMP anda
sequence recogmzed by urokmase uPA, located next to each other in any?
., order.
y ;
In one embodiment, ”the dam... (cm a combination /VuPA sEQ.N6."_-_
24/SEQ. No. 25 or a combination of uPA/MMP SEQ. No. 25/SEQ. No. 24.
In another embodiment, the domain (c) is a combination of MMP/uPA SEQ. No-
55 /SEQ. No.25 ora combination of uPA/MMP SEQ. No. 25/SEQ. No. 55.
In another embodiment, the domain (c) is a :comb1nat1on ofMMP/uPA SEQNo vj. _
56/SEQ-INoL'25 '"r'a ‘ " "
may be selected from the group consisting of SEQ. No.28, SEQ. No.29, SEQ.
No.30 and SEQ. No. 54, consisting of glycine and serine residues. Additionally,
the flexible steric linker may be any fragment of SEQ. No.28, SEQ. No.29 SEQ.
No.30 and SEQ. NO. 54, acting as a flexible stŒric linker, for example a
fragment Gly Gly Gly /GGG or a fragment Gly GIyIGG.
In one ment, the flexible steric linker may be also selected from single
amino acid residue such as single glutamic acid residue, cysteine, serine,
proline or glycine residue.
In other embodiment, the flexible steric linker may be any combination of
linkers consisting of SEQ. No.26, SEQ. No.27 SEQ. No.28, SEQ. No.29, SEQ.
No.30, SEQ. No. 54 and single amino acids residues of gLutamic acid residue,
cysteine, serine, proline or glycine.
Particular embodiments of the fusion protein of the invention are fusion
proteins comprising an antiangiogenic peptide selected from the group
consisting of the proteins ented by SEQ. No.1, SEQ. No.2, SEQ. No.4,
SEQ. No. 5, SEQ. No.6 and SEQ. No. 46, SEQ. No. 47 and SEQ. No.48, comprising
as an effector peptide a heptapeptide derived from VEGF.
Other specific embodiment of the fusion protein of the invention is fusion
n comprising an antlangiogenic peptide selected from the group
consisting of the proteins represented by SEQ. No.7 and SEQ. No.8, comprising
as an effector e sequences binding to CDI 3.
Other specific embodiment of the fusion protein of the ion is fusion
protein comprising an antiangiogenic e selected from the group
consisting of the proteins represented by SEQ. No.9, SEQ. No.10, SEQ. No. 11
and SEQ. No. 49 sing as an effector peptide a fragment of PDGF.
Other ic embodiment of the fusion n of the invention is fusion
protein comprising an àntiangiogenic. peptide selected from the group
consisting of the proteins represented by Not. SEQ. N0.12 and SEQ. No. 11,
comprising as an effector peptide tumstatin and and II fragments.
Other ic embodiment of the fusion protein of the invention is fusion
protein sing an antiangiogenic peptide selected from the group
consisting of the proteins represented by SEQ. No.14 and SEQ. No.15,
comprising as an effector e a fragment of EGF.
201.
and fragment II of in peptide.
A detailed description of the structure of representative fusion proteins
mentioned above are shown in Figures 1 to 3 and in Fig. 9, and in the Examples
presented herein below.
In accordance with the present ion, by the fusion protein it is meant a
single protein molecule containing two or more proteins or fragments thereof,
covalently linked via peptide bond within their respective peptide chains,
without additional chemical Linkers.
The fusion protein can also be alternatively described as a protein construct or
a chimeric n. According to the present invention, the terms "construct"
or "chimeric protein", if used, should be understood as referring to the fusion
For verification of the ure of the resulting peptide known methods of the
analysis of amino acid composition of peptides may be used, such as high
tion mass spectrometry que to determine the molecular weight of
the peptide. To confirm the peptide sequence protein sequencers can also be
used, which sequentially degrade the peptide and identify the sequence of
amino acids.
Preferably, however, the fusion protein of the invention is a inant
protein, ted by s of gene expression of a polynucteotide
sequence encoding the fusion protein In host cells.
A further aspect of the invention is the potynucleotide sequence, particularly
DNA sequence encoding a fusion n as defined above.
Preferably, the polynucleotide sequence, particularly DNA, according to the
invention, encoding the fusion protein as defined above, is a sequence
optimized for expression in E. coil.
Another aspect of the invention is also an expression vector ning the
polynucleotide sequence, particularly DNA sequence of the invention as defined
above.
r aspect of the invention is also a host cell comprising an expression
vector as defined above.
A preferred host cell for expression of fusion proteins of the invention is an E.
coil cell.
Methods for generation of recombinant proteins, including fusion proteins, are
well known. In brief, this technique consists in generation of polynucteotide
molecule, for example DNA molecule encoding the amino acid sequence of the
target protein and directing the expression of the target protein in the host.
Then, the target protein encoding polynucleotide molecule is incorporated Into
an appropriate expression vector, which ensures an efficient expression of the
potypeptide. Recombinant sion vector is then uced into host cells
for transfection/transformation, and as a result a transformed host cell is
produced. This is followed by a culture of transformed cells to overexpress the
target protein, purification of obtained proteins, and ally cutting off by
ivag t'h pii'rificatiohvo' he ”re
Cosmids plasmids 'or_ modified viruses can beused as expressmn vectors-for- the--
" 1ntroductio'"and-Implication of DNAsequences iHhost cells Typically plasmiidsilz-iug
____ar_e _used “as express1on vectors le plasmids are _well known a__11‘cin_fl_n_f;w_;
" commerc1ally‘available
Iifli the invention comprises -.
Express1on vector a- polynucleotide molecule
encoding. the fu51on protein of- the iOHand the necessary regulatory"
sequences for. transcription and translation of the codng sequence: :._
1ncorporated tho a‘ le host cell. Selection of regulatory seque'H'ces is.
" "
"'dependentpH the tyz ofhost cells aHd caH be ea31ly carried oat bya”'p 'son'."
such as B-gatactosidase, 6-glucuronidase, luciferase, chtoramphenicot
acetyltransferase or green fluorescent protein may be used.
Furthermore, the expression vector may contain signal sequence, transporting
proteins to the appropriate cellular tment, e.g. periplasma, where
folding is facilitated. onally a sequence encoding a [abet/tag, such as
Hislag attached to the inus or GST attached to the C-terminus, may be
present, which facilitates subsequent purification of the protein produced using
the principle of affinity, via affinity chromatography on a nickel column.
Additional sequences that protect the protein t proteolytic degradation
in the host cells, as well as sequences that increase its solubility may also be
present.
Auxiliary element attached to the sequence of the target n may block its
activity, or be detrimental for another reason, such as for e due to
toxicity. Such element must be removed, which may be accomplished by
enzymatic or chemical cleavage. In ular, a six-histidine tag HisTag or
other markers of this type attached to allow protein purification by affinity
chromatography should be removed, because of its described effect on the
Liver toxicity of soluble TRAIL protein. Heterologous expression s based
on various well-known host cells may be used, including prokaryotic cells:
bacterial, such as Escherichia coil or Bacillus is, yeasts such as
Saccharomyces cervisiae or Pichia is, and eukaryotic cell lines (insect,
mammalian, plant).
Preferably, due to the ease of culturing and genetic manipulation, and a large
amount of obtained product, the E. coil expression system is used. Accordingly,
the poLynucleotide ce containing the target sequence encoding the
fusion protein of the invention will be optimized for expression in E. coil, i.e. it
will contain in the coding sequence codons optimal for expression in E. coil,
selected from the possible sequence variants known in the state of art.
Furthermore, the expression vector will contain the above described elements
le for E. coil attached to the coding sequence.
Accordingly, in a preferred embodiment of the invention a polynucleotide
sequence comprising a sequence ng a fusion protein of the invention,
SEQ. No.1; SEQ. No.2; SEQ. No.3; SEQ. No.4; SEQ. No.5; SEQ. No.6; SEQ. No.7;
SEQ. No.8; SEQ. No.9; SEQ. No.10; SEQ. No.11, SEQ. No.12, SEQ. No.13; SEQ.
No.14 SEQ. No.15, SEQ. No.46; SEQ. No.47; SEQ. No.48; and SEQ. No.49.
In a preferred embodiment, the invention provides also an expression vector
suitable for transformation of E. coil, comprising the poLynucleotide sequence
selected from the group of polynucleotide sequences SEQ. No.31 to SEQ. No.45
and SEQ. No 50 to SEQ. No. 53 indicated above, as welli as E. coil cell
transformed with such an expression vector.
Transformation, i.e. introduction of a DNA sequence into bacteriaL host cells,
ularly E. coil, is usually performed on the competent cells, prepared to
take up the DNA for example by treatment with calcium ions at low
temperature (4° C), and then subjecting to the hock (at 37.42°C) or by
electroporation. Such techniques are well known and are usually determined by
the manufacturer of the expression system or are described in the literature
and manuals for laboratory work, such as Maniatis et al., Molecular Cloning.
Cold Spring Harbor, N.Y., 1982).
The procedure of overexpression of fusion ns of the invention in E. coil
expression system will be further described beLow.
The invention also provides a pharmaceutical ition containing the fusion
protein of the invention as defined above as an active ingredient and a suitable
pharmaceutically acceptable carrier, t and conventional auxiliary
components. The pharmaceutical composition will contain an effective amount
of the fusion n of the invention and pharmaceutically acceptabLe
ary components dissolved or dispersed in a carrier or diluent, and
preferably will be in the form of a pharmaceutical ition formulated in a
unit dosage form or formulation containing a plurality of doses. Pharmaceutical
forms and methods of their formulation as well as other components, carriers
and diluents are known to the skilled person and described in the literature.
For example, they are bed in the monograph Remingtons Pharmaceutical
Sciences, ed. 20, 2000, Mack Publishing Company, Easton, USA.
The terms "pharmaceutically acceptable r, diluent, and auxiliary
ingredients’ comprise any solvents, dispersion media, surfactants, antioxidants,
stabilizers, preservatives (e.g. antibacterial agents, antifungal agents),
ing agents, known in the art. The pharmaceutical composition of the
ion may contain various types of carriers, diluents and excipients,
depending on the chosen route of administration and desired dosage form, such
as liquid, solid and aerosol forms for oral, parenteral, Inhaled, topical, and
whether that ed form must be e for administration route such as by
injection. The preferred route of administration of the pharmaceutical
composition ing to the invention is parenterat, including injection routes
such as intravenous, intramuscular, subcutaneous, intraperitoneal,
umourous, or by single or continuous enous infusions.
In one ment, the pharmaceutical composition of the invention may be
administered by injection directly to the tumour. In another embodiment, the
pharmaceutical ition of the invention may be administered
intravenously. In yet another embodiment, the pharmaceutical ition of
the invention can be administered aneously or intraperitoneally. A
pharmaceutical composition for parenteral administration may be a solution or
dispersion in a pharmaceutically acceptable s or non-aqueous medium,
buffered to an appropriate pH and isoosmotic with body fluids, if necessary,
and may also contain antioxidants, buffers, bacteriostatic agents and soluble
substances, which make the composition compatible with the tissues or blood
of recipient. Other components, which may included in the composition, are
for example water, alcohols such as ethanol, polyots such as glycerol,
propylene glycol, liquid polyethylene glycol, lipids such as triglycerides,
vegetable oils, liposomes. Proper fluidity and the particles size of the
substance may be provided by coating substances, such as lecithin, and
surfactants, such as hydroxypropyl se potysorbates, and the like.
The composition may for example be administered at a dose of about I
microgram/kg of body weight to about 1000 mg /kg of body weight of the
patient, for example in the range of 5 mg/kg of body weight to 100 mg/kg of
body weight or in the range of 5 mg/kg of body weight to 500 mg/kg of body
weight. The fusion protein, and the compositions containing it exhibit
ncer or antitumor and can be used for the treatment of cancer diseases.
The ion also provides the use of the fusion protein of the invention as
defined above for treating cancer diseases in mammals, including humans. The
invention also provides a method of ng cancer diseases in mammals,
including humans, comprising administering to a t in need of such
treatment an anticancer effective amount of the fusion protein of the
invention as defined above, optionally in the form of appropriate
pharmaceutical composition.
The fusion protein of the invention can be used for the treatment of
hematologic malignancies, such as Leukaemia, granuLomatosis, myeloma and
other hematologic maligAàncies. The fusion protein can also be used for the
treatment of solid tumours, such as breast cancer, lung cancer, ing nonsmall
cell lung cancer, colon Icancer i pancreatic cancer, ovarian cancer,
bladder cancer, te cancer, kidney cancer, brain cancer, and the like.
Appropriate route of administration Of the fusion protein in the treatment of
cancer will be in ular parenteraL route, Which consists in administering
the fusion protein of the ion in the form of injections or infusions, in the
composition and form appropriate for this stration route. The invention
will be described In more detail in the following general procedures and
examples of specific fusion ns.
General procedure for overexpression of the fusion protein
Preparation of a plasmid
Amino acid sequence of the target fusion protein was used as a template to
3generate a DNA sequence encoding it, comprising codons optimized for
expression in Escherichia coil. Such a procedure allows to increase the
efficiency of a r step of target protein synthesis in Escherichia coil.
Resulting tide sequence was then automatically synthesized.
Additionally, the cleavage sites of restriction enzymes NdeI (at the 5’-end of
Leading strand) and XhOI (at the 3-end of Leading strand) were added to the
resulting gene encoding the target protein. These were used to clone the gene
into the vector pET28a (Novagen) They may be also be used for cloning the
s gene encoding the protein to other vectors Target protein expressed from this
co nstruct can be optionally ed at the N-terminus with a polyhistidire tag
(six inØs), preceded by a site recognized by thrombin, which subsequently
served to its purification via affinity chromatography. Some target were
sed without any tag, in particular without histidine tah, and those were
subsequently purified on SP Sepharose. The correctness of the resulting
construct was confirmed firstly by restriction analysis of isolated plasmids using
the enzymes NdeI and XhoI, followed by automatic sequencing of the entire
reading frame of the target protein. The primers used for sequencing were
complementary to the sequences of T7 promoter (5’-TMTACGACTCACTATAGG-
3) and T7 terminator (5-GCTAGTTA1TGCTCAGCGG-3) present in the vector.
Resulting plasmid was used for overexpresslon of the target fusion protein in a
cial E. coil strain, which was transformed according to the :
manufacturer’s recommendations. Colonies obtained on the selection medium.
(LB agar, kanamycin 50 pg/mI, 1% glucose) were used for preparing. an
overnight culture in LB liquid medium supplemented with kanarnycin (50 pg/mI)
and 1% gLucose After about 15h of growth in shaking incubator, the cultures
were used to inoculate the appropnate e
pressiOn and purification of fusion proteins - ØnØral procedure A
LB medium With kanani’cin (iO pg/mI) and 100 pM zinc sulfate was ated
with overnight culture. Thel culture Was incubated at 37°C until the l
density (OD) at 600 nm reached 0.60-0.80. Then IPTG was added to the final
concentrationin the range of 0.25 -1 MM After incubation (3.5 - 20h) with
g at 25°C the culture was fuged for 25 min at 6,000 g. ial
pellets were resuspended in a buffer containing 50 mM KH2PO4, 0.5 M NaCl, 10
mM imidazOle, pH 7.4. The suspension was sonicated on ice for 8 minutes (40%
amplitude, 15-second pulse, 10 s interval). The resulting extract was clarified
by centrifugation for 40 minutes at 20000 g, 4°C Ni Sepharose (GE Healthcare)
resin was pre treated by bration with buffer, which was used for
’hiM KH2P04 buffer With 0.5M NaCl, pH 74 Obtain fractionswere analyzed;
by SDS-PAGE Appropriate fractions were combined anddialyZed overnight ail’i
' ' ' '
4C against 50 mM Tris , pH 7.2, 150 mM NaCl, 500 mM L-arginine, 0.1'
,‘ar‘id “ ‘
' mM ZnSO4, "0.01% Tween at the "same’tim'e’ Histag, if present, was
cleaved with thrombin (1 :50). After the cleavage, thrombin was separated from
the target fusion protein expressed with by purification using
, Histag
Benzamidine SepharoseTM resin. Purification of target fusion proteins
expressed without Histag was performed on SP ose. The purity of the
product was analyzed by SDS-PAGE electrophoresis (Maniatis et al, Molecular
Cloning. ColdSpring Harbor, NY, 1982)
l V
' Overex resswn and unfication 0n"rotems al 'rocedure B 'j'
LB medium W'lth R l 00
(30pg/ml) and uMZinc ewasinoculatedi:
l '5 ’
Wlth overnight cultu Cult es'were'incubatedat 37°C until optical denSity-i'
(OD)at 600 nm'reached'_:r'0.‘60080 ThenIPTG wa C'addedto: thellfinal.":ll"'llli-I
. concentration ih the range 0 'l-1'imM After 20h incubation-lWith shaking at25°C I
the culture was centrifuged for 25 min at- 6000Q Bacterial cellsafteri‘j'.
l' '
- 'overexpressmn were disruptedin a French Press iri‘ a buffer containing 50 mM
KH2P04, 0. 5 M NaCl,. 10' mM ole, 5i'iiM betamercaptoethanol 0.5mM'l5.__‘_
PMSF (phenylmethylsulphonyl fluoride), pH 7.8 ing extract Was clanfiedf,
'25 by centnfugation_for__ 50 minutes at“"5000g TheNi-Sepharose resm was”‘
so."
mM imidazole, 10% glyc 05mM PMSFpH 7.5 O ainedfractions
ZnSO4, pH 74)
7.. ‘ Example
i 1. The fusion protein of SEQ. No1
----The n 6f-SEQ No.1 is 'a' fusion protein having the length 6f173 amino-«m-~-.-------v------
acids andthemass of 198 kDa, in Which at the N-terminus of the seqUe‘n‘Ce
-710 TRAIL 121-28‘1' hep‘tapeptide' derived from V'E'GF (SEQ. No.17) is attached as an!
effector peptide. Between the effector de and the 'sequence of TRAIL the"
le glycine steric linker (SEQ. No.28) is incorporated.
Structure of the fusion protein is shown schematically in Fig. 1, and its amino
acid sequence "and the" DNA'encoding sequence compriSin‘g s optimized 'for'._' '_ '
eXpressiori in E. c6li' are,respectively, SEQ No.1 antiSEQ. N0 31, as shown ifi'“
. -, the attached Sequence Listing
336‘ attached asan effector peptideBetween the- effector peptide andthen-5"
sequence of. TRAIL the fleXible glyCine steric linker (SEQ. No.28) is
. .
.3 incorporated
Structure of the fusion protein is shown schematically in Fig 1, and its amino
acid ce and the DNA encoding sequence compnsing codons optimized for
expression in E coli are, respectively, SEQ WO.Z and SEQ. No 32, as shown in
the attached Sequence Listing
The amino acid sequence SEQ No 2 was used as a tern to generate its
coding DNA sequence DNA SEQ No 32 A d containing the coding
sequence of DNA, with :A sequence allowing tol express His tag and a site
recognized by thrombin,: was ted and overexpression of thefusion
protein was carried out in accordance with the general procedures described
above. Overexpression was performed according to the general procedure A,
using E. coil BL2I (DE3) strain from Novagen. The n was separated by
electrophoresis in accordance with the l procedure described above.
Example 3. The fusion protein of SEQ. No.3
The fusion protein of SEQ. No.3 is a fusion protein having the length of 230
amino acids and the mass of 26,3 kDa, in which at the N-terminus of the
- ---I ---; ----- - --- - - _p% I - - - -
out in accôrdàncC with’ the general procedures described above.
Overexpression was performed according to the general procedure B, using E.
coil BL2I (0E3) strain from Novagen. The protein was separated by
electrophoresis in accordance with the general procedure described above.
Example 4. The fusion n of SEQ. N6.4
The protein of SEQ. No.4 is a fusion n having the length of 187 amino
acids and the mass of 21,4 kDa, in which at the N-terminus of the sequence
TRAIL 121-281 two sequences of heptapeptide derived from VEGF (SEQ. No.17)
are attached as an effector peptide. Between the two sequences of effector
peptide there is incorporated sequence of cleavage site ized by
metatLoprotease MMP (SEQ. No. 24), due to which the effector e wILL
undergo cleavage In the tumour environment. Between the ce of MMP
cleavage site and the sequence of effector protein there is incorporated a
single glutamic acid residue E. Between the effector peptide (SEQ. 17) and the
sequence of TRAIL there is incorporated flexible steric gLycine Linker (SEQ.
No.28).
Structure of the fusion protein is shown schematically in Fig. 1, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. cou are, respectively, SEQ. No.4 and SEQ. No.34, as shown in
the ed Sequence Listing.
The amino add sequence SEQ. No. 4 was used as a template to generate its
coding DNA sequence DNA SEQ. No. 34. A pLasmid containing the coding
sequence of DNA in two versions, one allowing to express His tag and a site
recognized by thrombin and the second without any tag, was generated and
overexpression of the fusion proteins was carried out in accordance with the
general procedures dØcribed above. Ovèrexpressiön was med according
to thel general procedure B, usrng E coil BL2IDE3pLysSR1L strain from
Stratageæe and Tuber (DE3) from NovagØn’. The ns were separated by
eLectrophoresis in accordance with the general procedure described above.
Example 5. The fusion protein of SEQ. No.5
The protein of SEQ. No.5 is a fusion protein having the Length of 187 amino
acids and the mass of 21,8 kDa, in which at the N-terminus of the sequence
TRAIL 121-281 two sequences of heptapeptide derived from VEGF (SEQ. No.17)
are attached as an Offector e. n the two sequences of effector
“33f33
peptidesthe proteincontains sequences of cleavage sites recognized by.- g1";- [-9
* urokinase- LIPA (SEQ No.25)and metalloprotease MMP (SEQ. No 24), due th_53 '_
' '
which the effector peptide Will undergo cleavage in the tumoUr enwronment '
vageSite the"sequence (if effe
Tingle glu mic and ‘ireSidueE. Additionally atthe; '
' It
reSidues areattached
Structure‘of' the fusion. proteinis Scheniatically in Fig. 1, and mama-5..
acid sequence and theDNA‘ericoding sequence comprising codons optimizednformi
expressiOn in E. coli "are, 'reépectiv‘ely;' SEQ.”NO.5 and "SEQ. No.35, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ. No. 5 Was 'used as a template to generate its
coding DNA sequence DNA SEQ. No.35. A plasmid containing the coding
sequence of DNA in two versions, one allowing to express His tag and a site
recognized by thrombin and the second without any tag, was generated and
overexpression of the fusion "proteins was carried out in accordance with the _'
general procedures de§ciiibed above. Over'eXpr'esSio'n Was med according}; '
to the general procedure A; using E. coli Tuner (DE3) strain from Novagen. The
ns wereseparated: by electrophoreSis in-accordance with the general
v procedure-d cnbed
j 20".;-
are attached as aneffector_5"peptide Between the two sequencesof effector-['5 ‘- 7‘
peptide the protein contains sequencesof cleavage Sites recogniZed byuPAf; ,I'
I orIpept‘de (SEQ 17) and theSGQuence‘of TRAILthe're‘is orated the; ‘5 I"...
ne flexible steric linker (SEQ. No.26)
Example 7. The fusion protein of SEQ. No.7
The protein of SEQ. No.7 is a fusion protein having the length of 168 amino
acids and the mass of 19,4 kDa, in which at the N-terminus of the ce
TRAIL 119-281 a sequence being a ligand of CDI 3 (SEQ. No.20) is attached as an
effector peptide.
ure of the fusion protein is shown schematically in Fig. 2, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. coU are, respectively, SEQ. No.8 and SEQ. No.38, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ. No, 8 was used as a template to generate its
coding DNA sequencei DNA SEQ. No. 38. A plasmid containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
recognized by thrombin, was generated and pression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpression was performed ing to the general procedure A,
using E. coil Tuner (DE3) strain from Novagen. The protein was separated by
electrophoresis in ance with the general procedure described above.
Example 9. The fusion protein of SEQ. No.9
The protein of SEQ. No.9 is a fusion protein having the length of 192 amino
is acids and the mass of 22,1 kDa, in which at the inus of the sequence
TRAIL 1 a ce of PDGF fragment (SEQ. No.22) is attached as an
effector peptide. Between the effector peptide and the ce of TRAIL the
protein contains sequences of cleavage sites - re nized by urokinase uPA (SEQ.
No. 25) and metalloprotease MMP (SEQ. No. 24). due to which the effector
peptide will undergo cleavage in the tumour environment.
Structure of the fusion protein is shown schematically in Fig. 2, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. coti are, respectively, SEQ. No.9 and SEQ. No.39, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ. No. 9 was used as a template to generate its
coding DNA sequence DNA SEQ. No. 39. A pLasmid containing the coding
sequence of DNA in two versions, one allowing to express His tag and a site
recognized by thrombin and the second without any tag, was ted and
pression of the fusion proteins was carried out in accordance with the
general procedures described above. Overexpression was performed according
to the general procedure A, using E. coil Rosetta (DO) strain from Novagen.
The proteins were separated by electrophoresis in accordance with the general
procedure described above.
Example 10. The fusion protein of SEQ. No. 10
The protein of SEQ. No. 10 is a fusion protein having the length of 216 amino
acids and the mass of 24,9 kDa, in which at the N-terminus of the sequence
TRAIL 5-281 a fragment of PDGF (SEQ. No.22) is ed as an or
S peptide. Between the sequence of effector peptide and the TRAIL domain the
protein contains sequences of cleavage sites recognized by uPA (SEQ. No. 25)
and metaUoprotease MMP (SEQ. No. 24), due to which the effector e Will
undergo cleavage in the tumour environment.
Structure of the fusion protein is shown schematically in Fig. 2, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. coli are, respectively, SEQ. No.10 and SEQ. No.40, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ. No. 10 was used as a template to generate its
coding DNA sequence DNA SEQ. No. 40. A plasmid containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
ized by thrombin, was generated and overexpression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpression was performed according to the general procedure A,
using E. call BL2I and Tuner(DE3)pLysS strains, both from Novagen. The
protein was separated by electrophoresis in accordance with the general
procedure described above.
Example 11. The fusion protein of SEQ. No. 11
The protein of SEQ. No.11 is a fusion protein having the Length of 226 amino
acids and the mass of 25,7 kDa, in which at the N-terminus of the sequence
5-281 a PDGF fragment (SEQ. No.22) is attached as an or peptide.
Between the effector peptide and the sequence of TRAIL the protein ns
sequences of cleavage sites recognized by urokinase uPA (SEQ. No. 25) and
metatloprotease MMP (SEQ. No. 24). due to which the effector peptide will
o ge in the tumour nment . Between the TRAIL sequence
and the sequence of cleavage site recognized by metalloprotease MMP the
protein contains also flexible glycine.cysteine-alanine linker (SEQ. No.27).
ure of the fusion protein is shown schematically in Fig. 2, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
Example 12. The fusion n of SEQ. No.12
The protein of SEQ. No.12 is a fusion protein having the length of 217 amino
acids and the mass of 25 kDa, in which at the N-terminus of the sequence TRAIL
121-281 fragments I and II of tumstatine (SEQ. No.18 and SEQ. No.19) are
attached as an effector peptide. Between the effector e and the
sequence of TRAIL the protein contains ces of cleavage sites ized
by urokinase uPA (SEQ. No. 25) mand etalloprotease MMP (SEQ. No. 24), due to
which the effector peptide will undergo cleavage in the tumour environment.
Between the sequence of TRAIL and the sequence of cleavage site recognized
by metaltoprotease MMP the n contains also a flexible linker consisting of
3 glycine residues Gly Gly My.
Structure of the fusion protein is shown schematically in Fig. 3, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. coti are, respectively, SEQ. No. 12 and SEQ. No.42, as shown in
the ed Sequence Listing.
The amino acid sequence SEQ. No. 12 was used as a template to generate its
coding DNA sequence DNA SEQ. No. 42. A plasmid containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
recognized by thrombin, was generated and overexpression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpression was med according to the general procedure A,
using E. coil MY (DE3) and Tuner(DE3)pLysS strains, both from Novagen. The
protein was separated by electrophoresis In accordance with the general
procedure described above.
Example 13. The fusion protein Of SEQ. N6.13
The protein of SEQ. NOM is a fusion n having the length of 220 amino
acids and the mass of 25,1 kDa, in which at the N terminus of the sequence
TRAIL 121-281 fragment II ofturnstatfn (SEQ. NO. 19) is ed as an èffector
peptide, and at the C terminus of the sequence TRAIL 121-281 fragment I of
tumstatin (SEQ. No. 18) is attached as an effector peptidØ. n the
effector e and the ce Of TRAIL the protein contains ces of
cleavage sites recognized by urokinäse uPA (SEQ. No. 25) and metalloprotease
MMP (SEQ. No. 24), due to which the effector peptide will undergo ge in
the tumour environment. Between the sequence of cleavage site recognized by
metatloprotease MMP and the sequence of TRAIL the protein contains three
glycine residues GLy GLy GLy and between the C-terminus of the sequence TRAIL
and fragment II of tumstatin a flexible linker consisting of 3 glyclne residues
GLy GLy GLy.
Structure of the fusion protein is shown schematically in Fig. 3, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. coli are, respectively, SEQ. No.13 and SEQ. No.43, as shown in
the attached Sequence Listing
The amino acid sequence SEQ. No 13 was used as a template to generate its
coding DNA sequence DNA SEQ. No 43 A pLasmid containing the coding
sequence of DNA, with a sequence ng to express His tag and a site
recognized by thrombin, was generated and overexpression of the fusion
protein was carned out in accordance with the general ures descnbed
abovei Overexpression was performed according to the general procedure B y
using E cot, 9.21 (M)strain from Novagen and BL2 1DE3pLysSRIL strain from
Stratagene The protein was separated by eLectrophoresis in accordance with
the general ure described above
Example 14 The fusion protein of SEQ. No 14
The protein of SEQ. No 14 is a fusion protein having the Length of 181 amino
acids and the mass of 21 kDa, in which at the N-terminus of the sequence TRAIL
1 a nt Of EF (SEQ. No.23) is attached as an effector peptide.
Between the effector peptide and the N-terminus of TRAIL domain the protein
contains sequences of cleavage sites recognized by urokinase uPA (SEQ. No. 25)
and metalloprotease MMP (SEQ No 56), due to which the effector peptide wilt
85 undergo cleavage in the tumour environment
Structure of the fusion protein is shown schematically in Fig. 3, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in E. doll are, respectively, SEQ. No.14 and SEQ. No.44, as shown in
the ed Sequence Listing.
S The Amino acid ce SEQ. No. 14 was used as a te to generate its
coding DNA sequence DNA SEQ. No. 44. A plasmid containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
recognized by thrombin, was generated and overexpression of the fusion
protein was carried out in accordance with the general procedures bed
above. Over sion was performed according to the general procedure B,
using E. coil BL2 I (DE3) strain from Novagen and BL2 IDE3pLysSRIL strain from
Stratagene. The protein was separated by electrophoresis in accordance with
the general procedure described above.
Example 15. The fusion n of SEQ. No. 15
The n of SEQ. No.15 is a fusion protein having the length of 217 amino
acids and the mass of 24,4 kDa, in which at the N-terminus of the sequence
hTRAIL95-281 a fragment of EGF (SEQ. No.23) is attached as an effector
peptide. Between the effector peptide and the N-terminus of TRAIL domain the
protein contains sequences of cleavage sites recognized by urokinase uPA (SEQ.
No. 25) and metalloprotease MMP (SEQ. No. 24), due to which the effector
peptide will undergo ge in the tumour environment. Between the
sequence of cleavage site ized by metalloprotease MMP and the
sequence of TRAIL the protein contains single praline residue followed by the
flexible glycine-cysteine-alanine Linker (SEQ. N0.26).
Structure of the fusion protein is shown schematically in Fig. 3, and its amino
acid sequence and the DNA encoding ce comprising codons optimized for
expression in E. coti are, respectively, SEQ. No.15 and SEQ. N0.45, as shown In
the attached Sequence Listing.
The amino acid sequence SEQ. No. 15 was used as atemplate to te its
coding DNA sequence DNA SEQ. No. 45. A plasmid containing the coding
sequence of DNA, with a sequence allowing to s His tag and a site
recognized by thrombin, was generated and overexpression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpression was performed according to the general procedure B,
using E. coil BL2I (DO) strain from Novàgen. The protein was separated by
electrophoresis in accordance with the general procedure described above.
Example 16. The fusion protein of SEQ. No.46
The fusion protein of SEQ. No.46 Is a fusion protein having the length of 211
amino adds and the mass of 24,4 kDa, in which at the N-terminus of the
sequence TRAIL 95-281 two heptapeptides derived from VEGF (SEQ. No.17)
Linked to each other are attached as effector peptides. Between the effector
peptides the protein contains sequences of cleavage sites recognized by
ase uPA (SEQ. No. 25) and metalloprotease MMP (SEQ. No. 55), due to
which the or peptide will undergo ge in the tumour environment.
Structure of the fusion protein is shown schematically in Fig. 9, and its amino
acid sequence and the DNA ng sequence comprising codons zed for
expression in E. coli are, respectively, SEQ. No.46 and SEQ. No.50, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ. No. 46 was used as a te to generate its
coding DNA sequence DNA SEQ. No.50, A plasmid containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
recognized by thrombin, was generated and overexpression of the fusion
n was carried out in accordance with the general procedures described
above. Overexpression was performed ing to the general procedure B,
using E. coil BL2 I (DE3) strain from Novagen. The protein was separated by
ophoresis in accordance with the general procedure described above.
Example 17. The fusion protein of SEQ. No.47
The fusion protein of SEQ. No.47 is a fusion protein having the length of 200
amino acids and the mass of 22,7 kDa, in which at the N-terminus of the
sequence TRAIL 1 two heptapeptides derived from VEGF (SEQ. No.17)
linked to each other are attached as effector peptides. Between the effector
peptides the protein contains sequences of cleavage sites recognized by
urokinase uPA (SEQ. No. 25) and metalloprotease MMP (SEQ. No. 55), due to
which the or peptide will undergo cleavage in the tumour environment.
Between the effector protein and the TRAIL domain the protein contains
subsequently flexible linker (SEQ. No. 26) promoting trimer formation and
flexible glycine -serine linker (SEQ. no. 54).
Structure of the fusion protein is shown schemäticaUyiA Fig. 9, and its amino
acid sequence and the DNA encoding sequence comprising codons optimized for
expression in ’E. coLi are, respectively, SEQ. No 47 and SEQ. No 51, as shown in
the attached q% Listing
S The amino acid sequence SEQ. No 47 was used as a template to te its
coding DNA sequence DNA SEQ No 51 A plasmid containing the coding
sequence of DNA, with a sequence allOwing to express His tag and a site
recognized by thrombin, was generated. and overexpression of the fusion
protein was carried out in ance with the general procedures described
above. pression was performed according to the general procedure B,
using E. coil BL2 I (DE3) strain from Novagen. The protein was separated by
electrophoresis in accordance with the general ure described above.
Example 18. The fusion protein of SEQ. No.48
The fusion protein of SEQ. No. 48 is a fusion protein having the Length of 192
amino acids and the mass of 21,9 kDa, in which at the N-terminus of the
ce TRAIL 120-281 two heptapeptides derived from VEGF (SEQ. No.17)
linked to each other are attached as effector peptides. Between the effector
peptides the n contains sequence of. cleavage site recognized by
urokinase uPA (SEQ. No 25), due to which the effector peptide will undergo
ge in the turnoutm virOne.en mntBetween the: Cffector protein and the
TRAIL domain the protein contains subsequently flexible linker (SEQ. No 26)
promoting tnmer forma’ormation and flexible glycine -senne linker (SEQ. no 54)
Structure of the fusion protein is shown schematically in Fig. 9, and its amino
acid sequence and the DNA encoding ce comprising codons optimized for
sion In E. coIl are, respectively, SEQ. No. 48 and SEQ. N6.52, as shown in
the attached Sequence Listing.
The amino acid sequence SEQ No 48 was used as a template to te its
coding DNA sequence DNA ’S Q. No 52. A ptasmid. Containing the coding
sequence of DNA, with a sequence allowing to express His tag and a site
recognized by thrombin, was generated and pression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpresslon was performed according to the general procedure B,
using E cot, BL2 I (DE3) strain from Novagen The protein was separated by
ophoresis in accordance with the l procedure described above
Example 19. The fusiOn prôtØin of SEQ. N649
The protein of SEQ No 49 is a fusion protein having the Length of 206 amino
acids and the mass of 23,3 kDa, in which at the N terminus of the sequence
TRAILI20 281 a PDGF fragment (SEQ No 22) is attached as an effector peptide
Between the effector e and the sequence of TRAIL the protein contains
sequences of cleavage sites recognized by urokinase UPA (SEQ. No. 25) and
metaLtoprotease MMP (SEQ. No. 55), due to which the effector peptide will
undergo cleavage in the tumour environment. Between the TRAIL sequence and
the sequence of ge site recognized by metalloprotease MMP the protein
contains also located subsequently flexible glydnecysteine-alanine linker
(SEQ. No.26) promoting trimer formation and flexible glycine -serine tinker
(SEQ. no. 54).
ure of the fusion protein is shown schematically in Fig.9, and its amino
acid sequence and the DNA encoding ce comprising codons optimized for
expression in E. coli are, respectively, SEQ. No. 49 and SEQ. No. 53, as shown
in the ed Sequence Listing.
The amino acid sequence SEQ No 49 was used as a template to generate its
coding DNA sequence DNA SEQ. No 53 A plasmid containing the coding
sequence of DNA, t a sequence alLowing to express - His tag and a site
recognized by in, was ed and overexpression of the fusion
protein was carried out in accordance with the general procedures described
above. Overexpression was performed ing to the general procedure A,
using E. coil BL21 (DE3) and Tuner(DE3)pLysS strains, both from Novagen. The
protein was separated by electrophoresis in accordance with the general
procedure bed above.
Example 20 Examination of anti tumor ty of the fusion proteins
Examination of anti tumor activity of the fusion proteins was carried out in
vitro in a cytotoxicity assay on tumor cell Lines and in vivo in mice For
companson purposes, rhTRAIL1 14-281 protein and placebo were used
1 Measurement of circular dichroism -determination of secondary structures
content of obtained ns
Quality of the preparations of fusion proteins in terms of their structure was
determined by circular dichroism (CD) for Ex 1, Ex 4, Ex 5, Ex 0 and Ex 14
Circular dlchrolsm is used for determination of secondary structures and
conformation of protein. CD method Uses l activity of the protein
structures, manifested in rotating the plane Of zation of tight and the
appearance of ellipticaL poLarization. CD spectrum of proteins in far ultraviolet
(UV) provides precise data on the conformation of the main polypeptide chain.
Dialysis
Samples of the protein to be analysed after ation into a buffer consisting
of 50 mM Tris-HCI pH 8.0, 100 mM NaCl, 10% ol, 0.1 mM ZnCl2, 80 MM
saccharose, 5mM DTT, pH 7,4 (or alternatively 5 mM NaH2PO4, 95 mM 4,
200 mM NaCl, 5 mM glutation, 0,1 mM ZnCl 2 , 10% glycerol, 80 mM sacharose, pH
8,0 for proteins overexpressed as described above but lacking the His-tag and
purified on SP Sepharose - marked in the results Table 5 with asterix ) were
dialysed in the dialysis bags (Sigma-Aldrich) with cut off 12 kDa. Dialysis was
performed t 100 fold excess (v/v) of buffer comparing to the n
preparations with stirring for several hours at 4°C. After dialysis was
completed, each preparation was centrifuged (25 000 rpm., 10 mm., 4°C) and
the appropriate supernatants were collected. Protein concentration in the
samples thus obtained was determined by rd method as an average of
triplicates.
Determination of protein concentration using rd method
In assays of n concentration of the reagent prepared by dissolving 17.5
mg of Coomassie G-250 in a mixture of ethanol (4.8% v I v) phosphoric acid (V)
(5.95% v I v) and water. To determine the protein concentration 1-10 mL of
sample was added to 800 ml of Bradford reagent. A reference sample
containing Bradford reagent and an appropriate volume of buffer in which the
dissolved protein was ined. The absorbance was read on a spectrophotometer
Cary 300 at a wavelength of 595 nrn after at least 5 minutes incubation
of the samples at room ature. The protein concentration was calculated
from the standard curve prepared for the BSA in the range of 10 concentrations
1-10 pg/mI. The starting n concentration was estimated after taking into
account the dilution during the preparation of the sample measurement.
Circular dichroism measurement
Measurement of circular dichroism for proteins in the concentration range of
0,1-2,7 mg/ml was performed on Jasco J-710 spectropolarimeter, in a quartz
cuvette with optical way 0.2 mm or mm. The measurement was performed
under the flow of nitrogen at 7 1/mm, which allowed to perform of the
measurement in the wavelength range from 195 to 250 nm. Parameters of the
measurement: spectral resolution of 1 nm; half width (if the light beam 1 nm;
sensitivity 20mdeg, the averaging time for one wavelength - 8 s, scan speed 10
nm/mm, ing of 3 measurements.
The results were presented as the average Of three ements. Circular
dichroism spectra for rhTRAILI 14-281 and proteins of Ex. 1, Ex. 4, Ex. 5, Ex. 9
and Ex. 14 are presented in Fig. 4.
Determination of secondary structure content
Obtained spectra were analyzed numerically in the range of 193-250 nm using
CDPro software. Points for which the voltage at the photomultiplier exceeded
700 V were omitted, due to too low signal to noise ratio in this wavelength
range.
The data obtained served for calculations of particular ary ures
content in the analyzed proteins with use of CDPro software (Table 1).
Table 1. Content of secondary ures in the analyzed ns
Protein ( I aDI) a-helix j3- sheet Schift Disorder
Ex.4 0.319 3.7% 39.4% 20.7% 36.2%
Ex.1 0.093 7.8% 8.6% 63.1% 20.5%
Ex.5 0.04 41.3% 15.0% 2.5% 41.2%
Ex.9 0.112 2.9% 41.0% 20.7% 35.4%
Ex. 14 0.244 0.2% 55.3% 17.1% 27.4%
rhTRAIL* 1.94% 50.97% 7.74% 39.35%
rhTRAIL 114-281 0.389 4.9% 33.7% 1 23.1% 38.3%
value obtained on the basis of crystaLLine structure 1 04V
Controls (rhTRAIL1I4-281) show CD spectrum teristic for the proteins
with predominantly type 3-sheet structures (sharply outlined ellipticity minimum
at the wavelength 220 nm). This confirms the calculation of secondary
structure components, which suggests a marginal number of a-helix elements.
The obtained result is also tent with data from the crystal structure of
hTRAIL protein and tenstic for the proteins of the invention of Ex 4, Ex
2. In vitro cell Line tests
Cell Lines
Table 2. Adherent cells
number of
CeLl line Cancer type Medium cells per well
(thousands)
CoLo 205 human colorectal RPMI + 10 FBS + penicillin
+ 5
ATCC 22 cancer streptomycin
HT-29 human colorectal McCoy’s + 10% FBS + penicillin
+ 5
ATCC # CCL-2 cancer streptomycin
DU-145 RPM!+ 10% FBS
human prostate cancer + penicillin +
ATCC 4 HTB-81 streptomycin
PC-3 RPM!
human prostate cancer + 10% FBS + penicillin +
ATCC #CRL-1435 streptomycin
MCF-7 MEM
human breast cancer + 10% FBS + penicillin +
ATCC #HTB-22 -
- streptomycin
MDA-MB-231 DMEM 10% FBS penicillin
- hu an breastm as cancer + +
+ 4. 5
ATCC # HTB-26 - _____streptomycin
UM-UC-3 human bladder ME + 10% FBS + penicillin
+ 3 5
ATCC # CLR-1749 cancer streptornycin
5W780 human bladder. DMEM + 10% FBS + penicillin
+ 3
ATCC #CRL-2169 cancer streptomycin
SW620 human colorectal DMEM + 10% FBS + penicillin
+ 5
ATCC 27 cancer streptornycin
BxPC-3 human pancreatic RPMI +.10%. FBS + peniciLlin
+ 4. 5
ATCC #CRL.1687 cancer streptomycin
NIH: OVCAR-3
human ovarian cancer I RPM! + 20% F,95 . 4- 0,01mg/mI
ATCC #HTB-161 insulin + penicillin + streptomycin
HepG2 MEM
human liver hepatoma + 10% FBS + penicillin +
ATCC HB-8065 omycin
293 Human embrional MEM + 10% FBS + LLin
+ 4
ATCC # CLR- 1573 kidney cells . streptomycin
ACHN MEM
human kidney cancer + 10% FBS + llin + ’I
ATCC #CcL-222 streptomycln
CAKI 2 McCoy’s
human kidney cancer + 10% FBS + llin +
ATCC # KTB-47 streptomycin
number of
Cell tine Cancer type Medium cells per well
(thousands)
HT144 McCoy’s ’+ 10% FBS + penicillin
human melanoma cells
ATCC HTB-63 streptomycin + 7
LNCaP RPMI 10% FBS
human prostate cancer + + penicillin + 4.5
ATCC #CRL- 1740 streptomycin
NCI-H69 human small cell lung RPMI + 10% FBS + penicillin
+ 22
ATCC# HTB-119 cancer streptomycin
Jurkat Al RPMI
human leukaemia + 10% FBS + penicillin
+ 10
ATCC#CRL-2570 streptomycin
/ Dx5 s
uterine cancer + 10% FBS + penicillin
ATCC# CRL-1 977 streptomycin +
-1 MEM
human lung cancer + 10% FBS + penicillin + 4
IITB-58 streptomycin
A549 RPMI
human lung cancer + 20% FBS + penicillin
+ 2.5
ATCC#_CCL-185 streptomycin
HCTI16 human colorectal s + 10% FBS + penicillin
+ 3
ATCC# CCL-247 cancer streptomycin
DMEM-F12 (1:1) + 5% horse serum
MCF1 OA mammary t/al
ATCC# CRL-10317 cells + 0,5pg/ml hydrocortisone + 4.5
10ig/ml Insulin + 20ng/ml EGF
MES-SA McCoy’s
e cancer + 10% FBS + penicillin
+ 3.5
ATCC# CRL-1976 streptomycin
PANC-1 human pancreatic DMEM + 10% FBS + penicillin
+ 5
CLS# 300228 cancer streptomycin
Table 3. Nonadherent cells:
Number of cells per
Cell line Cancer type Medium well (thousands)
NCI-H69 human small cell Lung RPMI+ 10% FBS + penicillin
ATCC# HTB 119 cancer, + streptomycin
Jurkat A3 . RPMI + 10% FBS + penicillin
human ia’’ 10
ATCC#CRL 2570 + streptomycin
HL60 human leukaemia RPMI + 20% FBS + penicillin
ATCC# CCL-240 + streptomycin
CCRF-CEM human leukaernia RPMI + 20% FBS + penicillin
ATCC# CCL-119 + strØptomycin
MIT cvtotóxidty. test,
MTT assay is ’a coLorirnetric assay used to measure proliferation, viability and
cytotoxicity of cells. It consists in decomposition of a yellow tetrazoUum salt
MIT (4,5-dimethyl2-thfazolyl)-2,5-diphehyttetrazolium brOmide) to the water
Insoluble purple dye fbrrnazan by mitochondrial enzyme succinate-tetrazolium
reductase 1. MIT reduction occurs only in living cells. Data analysis consists in
determining IC50 concentration of the protein (in ng/ml), at which the 50%
ion In the number of cells occurs in the population treated.compared to
l cells Results were analyzed using GraphPad Prism 5 0 software The
test was performed ing to the Literature descriptions (Celis, JE, (1998).
Cell Biology, a Laboratory Handbook, second edition, Academic Press, San
Diego; Yang, Y., Koh, LW, Tsai, JH., (2004); ement of viraL and chemical
factors with oraL cancer in Taiwan, Jpn J Clin OncoL, 34 (4), 176-183).
S Cell culture me, dium was diluted to a defined density (1O - cells per 100
p1). Then 100 p1 of appropriately diluted cell suspension was applied to a 96-
well plate in triplicates. Thus prepared cells were incubated for 24 h at 37°C in
% or 10% CO2, depending on the medium used, and then to the cells (in 100 p1
of medium) further 100 p1 of the medium containing various concentrations of
tested proteins were added. After incubation of the cells with tested proteins
over the period of next 72 hours, which is equivalent to 3-4 times of cell
on, the medium with the test protein was added with 20 ml of MTT
working solution [5 mg/mI], and tion was continued for 3 h at 37°C in 5%
CO2. Then the medium with MTT solution was removed, and formazan crystals
were dissolved by adding 100 p1 of DMSO. After stirring, the absorbance was
protein preparations 50 limit of 2000 ng/æil was adopted. Fusion ns
with an IC50 value above 2000 were considered inactive.
Cells for this test were selected so as to include the tumour cell lines naturally
resistant to TRAIL protein (the criterion of natural resistance to TRAIL: IC50 for
TRAIL protein > 2000), tumour cell lines sensitive to TRAIL protein and resistant
to doxorubicin Line MES-SA/DX5 as a cancer line resistant to conventional
anticancer medicaments.
Undifferentiated HUVEC cell line was used as a healthy control cell line for
assessment of the /toxicity of the fusion proteins in non-cancer cells.
The results obtained confirm the possibility of overcoming the resistance of the
cell lines to TRAIL by administration of certain fusion proteins of the invention
to cells naturally resistant to TRAIL. When fusion proteins of the invention into
the cells sensitive to TRAIL were administered, in some cases a clear and strong
iation of the potency of action was observed, manifesting in d IC50
values of the fusion protein compared with IC50 for the TRAIL alone.
Furthermore, cytotoxic activity of the fusion protein of the invention In the
cells resistant to classical anti-cancer medicament doxorubicin was ed,
and in some cases was stronger than activity of TRAIL alone.
The IC50 values above 2000 obtained for the non-cancer cell lines show the
absence of toxic s associated with the use of proteins of the invention for
healthy cells, which indicates potential low systemic toxicity of the protein.
Determination of cytotoxic activity of selected protein preparations against
extended panel of tumour cell lines
Table 5 presents the results of the tests of cytotoxic activity in vitro for
ed fusion proteins of the invention against a broad panel of tumour cells
from different organs, corresponding to the broad range of most common
cancers.
In Table 5, proteins that were originally expressed with histidine tag that was
subsequently removed are designated as a) at the Ex. No.. ns that were
originally expressed without histidine tag are designated as b) at the Ex. No..
Obtained IC50 values confirm high cytotoxic ty of fusion protein and thus
their ial utility in the treatment of cancer.
Continuous tion of preparations with cells over 72h (MTT test.,
Protein MES-SA MES-SA/Dx5 HT1 16 SK-MES-1 A549 MCFIOA
IC50 –SD 1050 –SD 1050 –SD 1050 –SD 1050 –SD IC50 –M
rhTRAILI14-281 >2000 32.2 240 173 31.3 12.2 233 >2000 >2000
9. a) 396 1.44 3.250 0.95 3.95 9.95 3.00 2.34 131.10 43.98 1420.5 [451.22
Ex. 14 2000 1738.1 .1.47 632.05 26.94 81.27 13.41 2000 2000
2000 6.822 2.83 38.66 11.34 5.80 1.93 2000 2000
Ex. 11 7.96 0.72 0.743 0.15 25.23 21.98 0.64 0.12 513.10 38.33 131.90. 77.92
Ex. 4 4.79 0.78 3.69 1.05 14.27 2.48 0.43 0.15 705.15 40.38 >2000
a) 1.03 0.08 0.699 0.06 2.48 2.03 0.54 0.34 9.95 0.88 13.01 2.17
. 13 83.03 21,.74 34.000 3.54 162.00 95.88 22.08 1.43 979.75 1.91 834.05 38.11
Table 5, continuation
Celt Line COLO 205 HT 29 SW 620 MCF 7 MDA-MB-231 DU 145 LNCaP PC 3
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
24.90 17 68 10000 10000 10000 10000 10000 2052,00 466,0 10000
95-281
i o 87 0 19 852 60 1.06 3650 0 832 329.20 23.83 0.54 64.33 22.31 254.00 4.124 980 60
SW 780 UM-UC-3 293 CAKI 2 SK-OV-3 OV-CAR-3 H69AR NCI-H69
Celt Irne mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
12000 42.43 2242 1367 10000 10000 10000 93.10 8,34 10000 10000
95-281
1 a)
3.78., 0.22 7.03 0.13 84350 3 80 230.50 61 50 2116 379 5.58 2.94 1530 137 1436
NCI-H460 BxPC3 HepG2 HT 144 ACHN JURKAT A3 HL60 CCRF-CEM
Cell. Line mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
5889 111.0 64.71 31.81 10000 1734 218.5 10000 10000 10000 10000
95-281
Ex. I a 7.71 0.09 2.57 0.43 633 89.73 4.47 1.11 71.19 8.92 5.09 2.40 1339 1357
Celt line COLO 205 HT 29 SW 620 MCF 7 MDA-MB-231 DU 145 LNCaP PC 3
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
2490 1768 10000 10000 10000 10000 10000 2052 4660 10000
95-281
a) 12 .24 :3.65 1600 1600 684.50 17 00 345 11,17 473 63.64 1600 1056
SW 780.. UM-UC-3 293 CAKI 2 SK-OV-3 OV-CAR-3 H69AR NCI-H69
Celt: line mean SD s mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
120.00 42.43 2242 1367 10000 10000 10000 93.10 8.34 10000 10000
95-281 -
38 46 1.03: 13 80 9 55 1600 1303 2.10 1600 79.25 27.93 1600 1600
NCI-H460 BxPC3 He G2 HT 144 ACHN A3 HL60 CCRF-CEM
SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
Cell line
rhTRAIL
5889 111.0 64.71 31 81 10000 1734 218.5 10000 10000 10000 10000
95-281
a) 118.90 28 14 93 90 1.41 1315 1389 62 57 44 1 89 510 00 76 37 30 15 4,00 1600 1600
Table 5, continuation
Cell Line COLO 205 HT 29 SW 620 MCF 7 MDA-MB-231 DU 145 LNCaP PC 3
mean SDI mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
24.90 17.68 10000 10000 10000 10000 10000 2052 466.0 10000
95-281
Ex. 9 a) 0 013 0 01 264 20 46 95 47 86 12,50 1025 190 10 1 276 0 40 15 77 9 81 32 90 27 01 463 90
SW 780 UM-UC-3 293 AKI 2 SK-OV-3 OV-CAR-3 H69AR ___
Cell tine mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
120.00 42.43 2242 1367 10000 10000 10000 93.10 8.34 10000 10000
95-281
Ex. 9 1.006 0.136 0.07 181.60 44.50 24.42 0.10 2500 0.456 0.64 818.60 11 30.67 2500
NCI-H460 BxPC3 HepG2 HT 144 ACHN JURKAT A3 HL66 CCRF-CEM
Cell Line mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
r TRAIL
5889 111.0 64.71 31.81 10000 1734 218.5 10000 10000 10000 10000
95-281
Ex. 9 0.004 0.01 0.001 9.78 1.31 0.845 1.20 1 4.46 1.98 0.615 1.00 2500 7500
CeLl Line COLO 205 HT 29 SW 620 MCF 7 MDA-MB-231 DU 145 LNCaP PC 3
SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
24.90 17.68 10000 10000 10000 10000 10000 2052.00 466.0 10000
95-281
3.04 0.32 8500 8500 8500 58.00 2.12 4062 1109 3250 766.51 8500
SW 780 UM-UC-3 293 - CAKI 2 3 OV-CAR-3 H69AR NCI-H69
CeLL line mean, SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
120.00 42.43 2242 1367 10000 10000 10000 93.10 8.34 10000 10000
95-281
Ex. 7 a) 7.01 2.58 7.63 0.51 6767 2188 8500 8500 15.14 2.62 8500 8500
NC!-H460 BxPC3 HepG2 HI 144 ACHN JURKAT A3 HL6O - CCRF-CEM
CeLL Line mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
5889 111.0 64.71 31.81 10000 1734 218.5 10000 10000 100001: 10000
95-281
0 7.11 1.52 7.94 3.19 8500 92.05 40.52 8500 8500 8500 8500
A549 HCTI 16 MCFIOA MES-SA/Dx5 SK-MES-1
Cell line
mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 7557 3454 >10000 29.15 12.66 39.35 8.13
95-281
Ex. 391.00 52.33 3.44 1169 <0.001 3.58 0.81
A549 H1 16 MCF I OA MES-SA MES-SAIDx5 SK-MES I .
NCI-H4601:
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 7557 3454 >10000 29.15 12.66 29.15 12.66 39.35 8.13 5889 111
95-281
Ex. 224.841 268.26 2473 500 99.27 51.24 0.36 0.25 0.007 0.00 5 22.76
A549 Hl 16 MCFIOA MES-SA MES-SA/Dx5 SK-MES-1 HT29 60
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 7557 3454 >°°°° 29.15 12.66 29.15 12.66 39.35 8.13 >°°°° 5889 111
95-281
Ex. 6 a) 422.70 0.014 129.90 0.01 0.0068 0.0043 1.41 69.19 18.79 0.02
Cell line PANCI PLCIPRF/5 Coto 205 HepG2 BxPc3 SW 620
mean I SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 >9000 24.90 17.68 >10000 64.71 31.81 >10000
95-281
6. 2.15 O.79 2.35 0.003 0.062 0.014 398.80 80.89
A549 MCFIOA MES-SA/6x5 SK-MES-t PANCI 293 UM-UC-3
Cell line mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 >10000 29.15 12.66 39.35 8.13 >10000 >10000 2242 1367
95-281
1 b)
346.75 102.18 147.80 3 96 .4.677 2.23 3.29 1.07 12.38 4.20 84.50 3.82 7.03 .0.13
A549 HCTII6 MCFIOA MES-SA MES-SA/Dx5 SK-MES-1 HT29 60
Celiline
mean SD mean- SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
> 1000( 7557 3454 >10000 >10000 29.15 1266 3935 8.13 >000 5889 111
95-281
a) 106.66 41.49 11.50 3.42 95.44 5.28 3.50 0.445 0.30 4.99 911.50 282.14 9.34 5.27
Table 5, continuation
Cell line PANCI PLCIPRF/5
mean SD mean SD
rhTRAIL
>10000 >9000
95-281
3.07 <0.001
A549 Hal 16 MCF1OA MES-SA MES-SAIDx5 SK-MES-1 NCI-H460 Colo 205
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 7557 3454 >10000 >10000 29.15 12.66 39.35 8.13 5889 111 24.90 17.68
95-281
Ex. 19 4.31 <0.001 0.19 <0.001 <0.001 <0.001 <0.001 0.004
HepG2 BxPC3 Cell line HC‘rl 16 MCFIOA MES-SA/Dx5 -1
Cell line
mean I SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL rhTRAIL
>00 64.71 31.81 7557 3454 >10000 1 29.15 12.66 39.35 8.13
95-281 95-281
a) a)
Ex. 19 0.20 0.013 Ex . 58.86 306.05 7.00 3.492 0.07 9.13 1.31
Cell line HCT1I6 BxPc3
mean SD mean SD
rhTRAIL 95-281 7557 3454 64.7f. 31 81
Ex. 14 27510 6746 796 1881
mean I SD I
I 8.13
SK-MES-1
mean SD
39.35 8.13
0.615
Table 5, continuation
HCTII6 MES-SA SK-MES-1 HT29 NCI-H460 PANCI PLCIPRFI5 Cola 205
Cell Line mean SD mean SD mean SD mean SD mea SD mean SD mean SD mean SD
rhTRAIL
7557 3454 >10000 39.35 8.13 >10000 5889 111 >10000 >9000 24.90
95-281 17.68
Ex. 5 b) 0.036 0.01 0.005 0.007 0.004 0.005 783,50 34,65 0.25 0,25 1.05 L0.56 5.54 12.24 3.65
HepG2 BxPc3 ACHN 3 Cell line DU 145 OVCAR3
Cell line
mean I SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL >10000 64.71 31.81 >10000 963.00 144.25 rhTRAIL 95-281 >10000 963 144.25
95-281
b) a)
9.27 0.36 0.44 0.5 0.09 <0.001 0.001 Ex. 7 4061 1109 15.14 2.62
HCTI 16 MES-SA/Dx5 SK-MES-1 NCI-H460 Coto 205 BxPc3 SW 780 UM-LJC-3
Cell line SD mean SD mean SD mean SD mea SD mean SD mean SD mean SD
mean
rhTRAIL 4A
7557 3454 29.15 12.66 39.35 8.13 5889 111 24.90 17.68 64.71 31.81 120 2242 1367
95-281
Ex 7.99 1.20 6.822 2.83 5.80 1.93 7.11 1.52 3.04 0.32 7.93 3.19 7.01 2.58 7.63 0.51
Table 5, continuation
MCFIOA MES-SA MES-SAIDx5 SK-MES-1 HT29 NCI-H460 PANCI F/5
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL
>10000 >10000 29.15 12,66 39.3 8.1 >10000 5889 111 >10000 >9000
95-281
Ex. 9 b) 10.30 4.15 <0.001 0.008 0.02 264.2 46.9 0.87 0.01 0.025 0.035 21.87 3.58
ACHN SW 780 UM4JC3 Cell line PANCI PLC/PRF/5 NCIH460 PANCI
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL rhTRAIL
120 42.43 2242 1367 9000 5889 111 >10000
95-281 95-281
Ex. 9 b) 4.46 1.98 <0.001 0.14 0.07 Ex. 15 a) 128.00 3722 15.20 128
Hal 16 MESSA MESSA/Dx5 SKMES1 PC 3 Cell line UMUC3
Cell line
mean SD mean SD mean SD mean SD mean SD mean SD mean SD
rhTRAIL rhTRAIL
7557 3454 >10000 29.15 12.66 39.3 8.13 >10000 2242 1367
95-281 95-281
Ex. 4 b) 14.27 2,48 4.79 0.78 3.69 1.05 0.43 0.15 1056 180.9 Ex. 14 a) 30.37 3.10
3. Antitumour effectiveness of fusion proteins in vivo on xenografts
Antitumour activity of protein preparations was tested in a mouse model of
human colon cancer HCTI16, Co1o205 and 5W620 cells, human non-small cell
lung cancer A549 and NCI-H460-Luc2 cells, human ma PLC/PRF/5 (CLS)
cells, human pancreatic carcinoma PANC-1 cells, human liver carcinoma HepG2
cells, human large-cell lung carcinoma NCI-H460 cells, and human uterine
carcinoma MES-SA/ Dx5 multidrug resistant cells.
Cells
The HCT116 and A549 (ATCC CCL-185) cells were maintained in RPMI 1640
medium (Hyclone, Logan, UT, USA) mixed in the ratio of 1:1 with Opti-MEM
(Invitrogen, Cat.22600-134) supplemented with 10% fetal calf serum and 2 MM
glutamine. On the day of mice grafting, the cells were detached from the
support by washing the cells with trypsin (Invitrogen), then the cells were
fuged at 1300 rpm, 4°C, 8 mm., suspended in HBSS buffer (Hanks
medium), counted and diluted to the concentration of 25x10 6 cells/mi.
The PLC/PRF/5 (CLS), SW620 and PANC-1 cells were maintained in DMEM
(HyClone, Logan, UT, USA) supplemented with 10% fetal calf serum and 2 mM
glutamine. On the day, o. grafting, the cells were detached from the
support by washing the cells with trypsin (Invitrogen), then the cells were
centrifuged at 1300 rpm, 4°C, 8 mm., suspended in HBSS buffer (Hanks
), d and diluted to the concentration of 25x10 6 cells/mi.
The HepG2 cells were maintained in MN: (HyClone, Logan, UT, USA)i
mented with 10% fetal calf serum and 2 mM glutamine. On the day of mice
grafting, the cells were detached from the t by washing the cells with
trypsin (Invitrogen), then the cells were centrifuged at 1300 rpm, 4°C, 8 mm.,
suspended in HBSS buffer (Hanks medium), counted and diluted to the
concentration of 25x10 6 cells/mi.
The NCI-H460-Luc2, NCI-H460 and 5 were maintained in RPMI1640
(HyClone, Logan, UT, USA) mented with 10% fetal calf serum and 2 MM
giutamine. On the day of mice grafting, the cells were detached from the
t by washing the cells with trypsin (Invitrogen), then the cells were
centrifuged at 1300 rpm, 4°C, 8 mm., suspended in HBSS buffer (Hanks
medium), counted and diluted to the concentration of 25x10 6 cells/mi
The MES-SA/Dx5 cells were hiaintainèd in McCoy’s (HyClone, Logan, UT, USA)
supplemented with 1096 fetal calf serum and 2 mM glutamine. On the day of mice
grafting, the cells were detached from the support by washing the cells with
trypsin (Invitrogen), then the cells were centrifuged at 1300 rpm, 4°C, 8 min.,
suspended in HBSS buffer (Hanks medium), counted and diluted to the
concentration of 25x10 6 cells/mi.
Mice
Examination of mor activity of proteins of the invention was conducted on
4-5 week-old or 79 week-old CD- nude (Crl:CD1Foxnhlu 1) or on 4-5 week old
Crl:SHO-PrkdcHrAr mice ed from Charles River Germany or 4-5 week-old
Cby.Cg-foxnl (nu)/J mice obtained from Centrum Medycyny Dowiadczalnej in
Bialystok. Mice were kept under specific pathogen-free conditions with free
access to food and demineralised water (ad libitum). All experiments on animals
were d in accordance with the guidelines: disciplinary ples and
Guidelines for the Use of Animals in ch, Marketing and Education" issued
by the New York Academy of Sciences Ad Hoc Committee on Animal Research
and were approved by the IV Local Ethics Committee on Animal Experimentation
In Warsaw (No. 71/2009).
The course and evaluation of the expenments
Tumor size was measured using an electronic calliper, tumor volume was
calculated using the formula: (a 2 x b)/2, where a = shorter diagonal of the 25
tumor (mm) and b = Longer diagonal of the tumor (mm). tion of tumor
growth was calculated using the formula:
Human colon cancer model
mice Cr[:CDI-FoxnV7t1 l
On day 0 mice Crl:CDI-Foxn Inu 1 were grafted subcutaneously (Sc) in: the right.
side with 5x106 of HCTII6 cells suspended in 0.2 ml HBSS buffer by means of a
syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
- 60-90 mm (day 14), mice were randomized to obtain the average size of
tumors in the group of - 70 mm 3 and assigned to treatment . The
treatment groups were administered with the preparations of fusion proteins of
the invention of Ex. 1 (10 mg/kg), Ex. 4 (10 mg/kg),, Ex. 5 (10 , and Ex.
9 (10 mg/kg), and rhTRAILII4-281 (10 mg/kg) as a comparison. The preparations
were stered intravenously (1. v.) daily for ten days. When a therapeutic
group reached the average tumor size of - 1000 mm 3, mice were sacrificed by
disruption of the spinal cord. The control group received rhTRAILI .
The mental results obtained in mice Crt:CD1Foxnhlu burdened with
HCTI 16 colon cancer treated with fusion proteins of the invention of Ex. I , Ex.
4, Ex. 5 and Ex. 9 and comparatively with rhTRAIL114-281 are shown in Fig. 5 as
a diagram of changes of the tumor volume and in Fig. 6 which shows tumor
growth inhibition (%TGI) as the percentage of control.
The s of experiments presented in the graphs in Figures 5 and 6 show that
administration of the fusion proteins of the invention of Ex. 1, Ex. 4, Ex. 5 and
Ex. 9 caused tumor HCT116 growth inhibition, with TGI respectively 67.8; 69.8;
84.4 and 66.2% relative to the control on 27th day of the experiment. For
rhTRAILII4-281 used as the comparative reference, a slight inhibitory effect on
tumor cell growth was obtained relative to the l, with TGI at the level of
44%. Thus, fusion proteins of the invention exert much stronger effect compared
to rhTRAILI14-281 atone.
Mice Crl :CD1Foxn1tLI
HTI 16 model
On day 0 mice Crl:CD1.Foxn1LI were grafted subcutaneously (Sc) in the right side
with 5x10 6 of HCT1 16 cells suspended in 0.2 ml HBSS buffer by means of a
syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
- 50-78 mm (day 8), mice were randomized to obtain the e size of tumors
in the group of - 63 mm 3 and assigned to treatment groups. The treatment
groups were administered with the preparations of fusion proteins of the
invention of Ex. 5. (10 mg/kg), Ex. 4. (10 mg/kg), Ex. 9 (10 mg/kg), Ex. 1 (10
mg/kg) and rhTRAIL114-281 (10 mg/kg) as a comparison against formulation
buffer (50 mM Trizma Base, 150 mM NaCl, 80 mM Saccharose, 250 mM L-arginine,
1 mM glutation, Zn 2 0.1 mM, pH 7.3) as a control. The preparations were
administered intravenously (i.v.) daily for five days, followed by (after 2-days
break) another five daily administrations. When a therapeutic group reached the
average tumor size of - 1000 mm 3 , mice were sacrificed by disruption of the
spinal cord. The control group ed rhTRAILI 14-281.
The experimental results obtained in mice Crl:CD1-Foxnjnu burdened with
HCTI16 colon cancer treated with fusion proteins of the invention of Ex. 5. , Ex.
4, Ex. 9, Ex. 1 and atively with rhTRAILII4-281 are shown in Fig. 10 as a
is diagram of changes of the tumor volume and in Fig. 11 which shows tumor
growth inhibition (%TGI) as the percentage of control.
The results of ments presented in the graphs in Figures 10 and 11 show
that administration of the fusion proteins of the invention of Ex. 5. , Ex. 4. , Ex.
9, and Ex. 1 caused tumor HCTII6 growth inhibition, with TGI respectively 80%,
27th day of the experiment. For
79%, 66% and 68% relative to the control on
LII4-281 used as the comparative reference, a slight inhibitory effect on
tumor cell growth was obtained relative to the control, with TGI at the level of
44.3%. Thus, fusion ns of the invention exert much stronger effect
compared to rhTRAILI14-281 alone.
Mice Crl : SHOPrkdc IdH rt
HTI 16 model
intravenously (I. V.) six times every second day. When a therapeutic group
reached the e tumor size of - 1000 mm 3, mice were sacrificed by
disruption of the spinal cord. The control group received rhTRAILII4-281.
The experimental results obtained in mice Crl:SHOPrkdcHrh1r burdened with
HCTI 16 colon cancer treated with fusion proteins of the invention of Ex. 6 (30
mg/kg), Ex. 1 1 (45 mg/kg) and comparatively with rhTRAILI 14-281 are shown in
Fig. 12 as a diagram of changes of the tumor volume and in Fig. 13 which shows
tumor growth tion (%TGI) as the percentage of control.
The results of experiments presented in the graphs in Figs 12 and 13 show that
administration of the fusion ns of the invention of Ex. 6 and Ex. 11 caused
tumor HCTII6 growth inhibition, with TGI respectively 42% and 44.5% relative to
the control on 32w’ day of the experiment. For L114-281 used as the
comparative reference, a slight inhibitory effect on tumor cell growth was
obtained relative to the control, with TGI at the level of 5.65vo. Thus, fusion
proteins of the ion exert much stronger effect compared to rhTRAILII4-
281 alone.
Mice Crl:SHO-PrkdCsc Id Hr hr
The experimental results obtained in mice O . -Prkdcsc idHrhr burdened with
Co(o205 colon cancer treated with fusion proteins of the invention of Ex. 6 (30
mg/kg), Ex. 19 45 mg/kg) and comparatively with rhTRAIL114-281 are shown in
Fig. 14 as a diagram of changes of the tumor volume and in Fig. 15 which shows
tumor growth inhibition (%TGI) as the percentage of control.
The results of ments presented in the graphs in Figures 14 and 15 show
that administration of the fusion proteins of the invention of Ex. 6 and Ex. 19
caused tumor Colo205 growth inhibition, with TG I respectively 100% and 100%
relative to the l on 33 t day of the experiment. For rhTRAJLII4-281 used
as the comparative reference, a slight inhibitory effect on tumor cell growth was
obtained relative to the control, with TGI at the Level of 18.8%. Thus, fusion
size of - 1000 mm 3, mice were sacnficed by disruption of the spinal cord The
control group received rhTRAILII4 281
The expenmental results obtained..in Cr1 SHO PrkdcHr’ burdened withkid h
SW620 colon cancer treated with fusion proteins of the in of Ex. 6 Ex 11
S and comparatively with rhTRAILII4-281 are shown in Fig. 16 as a diagram of
changes of the tumor volume and in Fig. 17 which shows tumor growth tion
(%TGI) as the percentage of control.
The results of experiments presented in the graphs in Figures 16 and 17 show
that administration of the fusion ns of the invention of Ex. 6 and Ex. 11
caused tumor SW620 growth inhibition, with TGI tively 62% and 23 relative
to the control on 31st day of the experiment. For rhTRAILI14-281 used as the
comparative reference, no inhibitory effect on tumor cell growth was obtained
relative to the control, with TGI at the level of -9%. Thus, fusion proteins of the
invention exert much stronger effect compared to rhTRAILII4-281 alone.
is The tested fusion proteins did not cause significant side effects manifested by a
decrease in body weight of mice (i.e. less than 10% of the baseline body weight).
This shows Low systemic toxicity of the protein.
Human lung cancer model
Mice Crl:CDI-Foxnl" t’ I
On day 0 mice CrL:CDI-Foxnl m’ I were grafted subcutaneously (Sc) in the right
side with 5x10 6 of A549 cells ded in 0.2 ml HBSS buffer by means of a
syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
100 mm (day 14), mice were ized to obtain the average size of
The experimental results obtained in mice CrL:CD1Foxn1L ed with A549
Lung cancer treated with fusion proteins of the invention of Ex. I and
comparatively with LI14-281 are shown in Fig. 7 as a diagram of changes
of the tumor volume and in Fig. 8 which shows tumor growth inhibition (%TGI) as
the percentage of control.
The results of ments presented in the graphs in s 7 and 8 show that
administration of the fusion protein of the invention of Ex. I caused tumor A549
growth Inhibition, with TGI 44.8% relative to the control on t day of the
experiment. For rhTRAILI14-281 used as the comparative reference, a slight
inhibitory effect on tumor cell growth was obtained relative to the control, with
TGI at the level of 16.5%. Thus, fusion proteins of the invention exert much
stronger effect compared to TRAIL alone.
Cby.Cg-foxnl (nu)/J
On day 0 mice Cby.Cg-foxnl(nu)/J were grafted subcutaneously (sc) in the right
side with 5x10 6 of A549 cells suspended in 0.2 ml HBSS buffer by means of a
syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
60-90 mm 3 (day 19), mice were randomized to obtain the average size of
tumors in the group of - 75 mm3 and assigned to treatment groups. The
treatment groups were administered with the preparations of fusion protein of
the ion of Ex.l (15 mg/kg) and rhTRAILII4-281 (20 mg/kg) as a comparison
t water for ion as a control. The ations were stered
intravenously (i.v.) six times every second day. When a therapeutic group
reached the average tumor size of - 1000 mm 3 , mice were sacrificed by
disruption of the spinal cord. The control group received rhTRAILI 14-281.
The experimental results obtained in mice Cby.Cg-foxnl(nu)/J burdened with
A549 lung cancer treated with fusion protein of the invention of Ex.1 and
comparatively with rhTRAILII4-281 are shown in Fig. 18 as a diagram of changes
of the tumor volume and in Fig. 19 which shows tumor growth inhibition (%TGI)
as the percentage of control.
The results of experiments presented in the graphs in Figures 18 and 19 show
that administration of the fusion protein of the invention Ex. 1 caused tumor
33th
A549 growth inhibition, with TGI 44.8% relative to the control on day of the
experiment. For rhTRAILII4-281 used as the comparative reference, a slight
inhibitory effect on tumor cell growth was obtained ve to the control, with
TG at the level of 16.6%. Thus, fusion proteins of the invention exert much
stronger effect compared to rhTR4IL1I4-281 alone.
Mice: Cri:SHO-Prkdc sc
A. On day 0 mice C rl : SHOP rkdc H rhrwere grafted subcutaneously (Sc) in the
right side with 5x106 of NCI-H460 cells ded in 0.2 ml HBSS buffer by means
of a syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size
of - 0 mm 3 (day 13), mice were randomized to obtain the average size of
tumors in the group of - 160 mm 3 and assigned to treatment groups. The
treatment groups were administered with the preparations of fusion protein of
the invention of Ex. 6 (30 mg/kg) and rhTRAIL1I4-281 (30 mg/kg) as a
comparison t against formulation buffer (5 mM NaH2PO4, 95 mM Na2HPO4,
200 mM NaCl, 5 mM gLutatione, 0,1 mM ZnCl2, 10% glycerol, 80 mM saccharose,
pH 8.0) as a control. The preparations were administered intravenously (i.v.) six
times every second day. When a therapeutic group reached the average tumor
size of - 1000 mm 3 , mice were sacrificed by disruption of the spinal cord. The
control group ed rhTRAILII4-281.
The experimental results obtained in mice Crl:SHO -PrkdcHridd burdened with
NCI-H460 lung cancer treated with fusion protein of the invention of Ex. 6 and
comparatively with rhTRAIL114-281 are shown in Fig. 20 as a diagram of s
Of the tumor volume and in Fig. 21 which shows tumor growth inhibition (%TGI)
as the percentage of control.
The results of experiments presented in the graphs in Figures 20 and 21 show
that administration of the fusion protein of the invention Ex. 6 caused tumor
NCI-H460 growth tion, with TGI 88.5% relative to the control on 28 th’ day of
the experiment. For rhTRAILII4-281 used as the comparative reference, a slight
tory effect on tumor cell growth was obtained relative to the control, with
TGI at the Level of 17.5%. Thus, fusion proteins of the ion exert much
stronger effect compared to rhTRAIL1I4-281 alone.
B.On day 0 mice CrL:SHO.PrkdcdHrwere grafted subcutaneously (Sc) in the
right side with 7x10 6 of A549 cells suspended in a mixture of 0.2 ml
HBSS:Matrigel in ratio 3:1 by means of a syringe with a 0.5 x25 mm needle
(Bogm ark ). When tumOrs reached the size of - 140-165 mm 3 (day 19), mice were
ized to obtain the average size of tumors in the group of - 150 mm 3 and
assigned to treatment . The treatment groups were administered with the
preparations of fusion proteins of the invention of Ex.5 (60 mg/kg), Ex. 6 (50
mg/kg), Ex. 11(50 mg/kg) and L1I4-281 (20 mg/kg) as a comparison
against t formulation buffer (5 mM NaH2PO4, 95 mM Na2HPO4, 200 mM
NaCL, 5 mM glutatione, 0.1 mM ZnCl2, 100 mM L-arginine, 80 mM sacharose, pH
8.0) as a control. The preparations were administered intravenously (i.v.) six
times every second day. When a therapeutic group reached the average tumor
size of - 1000 mm 3, mice were sacrificed by disruption of the spinal cord. The
control group received LII4-281.
The experimental results ed in mice CrL:SHO-Prkdc’ 1Hr burdened with
A549 lung cancer treated with fusion proteins of the invention of Ex.5, Ex. 6,
Ex. 11 and comparatively with rhTRAILI 14-281 are shown in Fig. 22 as a diagram
of changes of the tumor volume and in Fig. 23 which shows tumor growth
inhibition (%TGI) as the percentage of control.
The s of experiments presented in the graphs in Figures 22 and 23 show
that administration of the fusion proteins of the invention Ex.5, Ex. 6,, and Ex.
11 caused tumor A549 growth Inhibition, with TGI respectively 39.3%, 39.3% and
28% relative to the control on 38th day of the experiment. For rhTRAILII4-281
used as the comparative reference, a slight inhibitory effect on tumor cell
growth was obtained relative to the l, with TGI at the level of 5.3%. Thus,
fusion proteins of the invention exert much stronger effect compared to
rhTRAILI 14-281 alone.
C. On day 0 mice OPrkdc1dHr were grafted subcutaneously (sc) in the
right side with 7x106 of NCI-H460-Luc2 cells suspended in 0.1 ml HBSS by means
of a syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size
of - 100-120 mm 3 (day 19), mice were randomized to obtain the average size of
tumors in the group of - 110mm 3 and assigned to treatment groups. The
treatment groUps were administered with the preparations of fusion protein of
the invention of Ex.5 (first administration 40 mg/kg, followed by 30 mg/kg), and
rhTRAILII4-281 (20 mg/kg) as a comparison against against formulation buffer
(19 MM NaH2PO4, 81 MM Na2HPO4, 50 mMNaCl, 5 MM gLutation, 0.1 mM 2nC[2,
10% glycerol, pH 7.4) as a control. The preparations were administered
intravenously (i.v.) six times every second day. When a therapeutic group
reached the average tumor size of - 1000 mm 3, mice were sacrificed by
disruption of the spinal cord. The control group received rhTRAILII4-281.
The mental results ed in mice C rL : SHO.PrkdctdHrt1r burdened with
NCI-H460-Luc2 lung cancer treated with fusion protein of the invention of Ex.5
and comparatively with LI14-281 are shown in Fig. 24 as a diagram of
changes of the tumor volume and in Fig. 25 which shows tumor growth tion
(%TGI) as the percentage of control.
The results of experiments ted in the graphs in Figures 24 and 25 show
is that administration of the fusion protein of the invention of Ex.5 caused tumor
60-Luc2 growth inhibition, with TGI 97.2% relative to the control on 29th
.......... ...- ..-. - , ’- ..
right side with 7x106 of A549 cells suspended in 0.1 ml mixture of HBSS:Matrigel
by means of a syringe with a 0.5 x25 mm needle (Bogmark). When tumors
reached the size of 100-120mm 3 (day 17), mice were randomized to obtain the
average size of tumors in the group of - 110m m 3 and assigned to treatment
groups. The treatment groups were administered with the preparations of fusion
proteins of the invention of Ex.5 (50 , Ex.1 (50 mg/kg), and rhTRAILII4-
281 (20 mg/kg) as a comparison against against formulation buffer (19 MM
NaH2PO4, 81 MM Na 2HPO4, 50 mM NaCl, 5 mM glutation, 0.1 mM ZnCl2, 10516
tumor size of - 1000 mm 3, mice were iced by disruption of the spinal cord.
The control group received rhTRAILI 14-281.
The experimental results obtained in mice C rl : SHOP rkdc dH r hr burdened with
A549 lung cancer d with fusion proteins of the invention of Ex.5 , Ex.1 and
comparatively with rhTRAIL114-281 are shown in Fig. 26 as a m of changes
of the tumor volume and in Fig. 27 which shows tumor growth inhibition (%TGI)
as the percentage of control.
The results of experiments presented in the graphs in Figures 26 and 27 show
that stration of the fusion proteins of the invention of Ex.5 and Ex.1
caused tumor A549 growth inhibition, with TGI respectively 52.5% and 41.6%
relative to the control on 34 th day of the experiment. For rhTRAILII4-281 used
as the comparative nce, a slight inhibitory effect On tumor cell growth was
obtained relative to the control, with TGI at the Level of 21.8%. Thus, fusion
proteins of the invention exert much stronger effect compared to rhTRAIL114-
281 alone.
Liver cancer model
Mice O-PrkdCs dd On day 0 mice C rl: SHOP rkdc H rtw were grafted
subcutaneously (Sc) in the right side with 5x10 6 of PLC/PRF/5 cells suspended in
0.2 ml HBSS buffer by means of a syringe with a 0.5 x25 mm needle (Bogmark).
When tumors reached the size of - 190-220 mm 3 (day 31), mice were
randomized to obtain the average size of tumors in the group of - 200 mm 3 and
assigned to treatment . The treatment groups were administered with the
preparations of fusion protein of the invention of Ex. 6 (40 mg/kg) and Ex. 11
(50 mg/kg), and rhTRAILII4-281 (30 mg/kg) as a comparison t formulation
buffer (5 mM NaH2PO4, 95 mM Na2HPO4, 200 mM NaCl, 5 mM glutatione, 0.1 mM
ZnCl2, 10% glycerol, 80 mM rose, pH 8.0) as a control. The preparations
were administered intravenously (i.v.) following the schema: 4 administration
every third day and 2 administrations every second day. When a therapeutic
group reached the average tumor size of - 1000 mm 3 , mice were sacrificed by
disruption of the spinal cord. The control group received rhTRAILI 14-281.
The experimental results obtained in mice Crt:SHO-Prkdc’c"Hr hr ed with
PLC/PRF/5 Liver cancer treated with fusion proteins of the invention of Ex. 6 and
Ex. 11 and atively with rhTRAIL1I4-281 are shown in Fig. 28 as a diagram
of changes of the tumor volume and in Fig. 29 which shows tumor growth
inhibition (%TGI) as the percentage of control.
The results of experiments presented in the graphs in Figures 28 and 29 show
that administration of the fusion proteins of the invention Ex. 6 and Ex. 11
caused tumor PLCIPRF/5 growth inhibition, with TGI respectively 70.6% and
63.8% relative to the control on 49th day of the ment. For rhTRAILII4-281
io used as the comparative reference, the inhibitory effect on tumor cell growth
was not obtained relative to the control, with TGI at the level of -18%. Thus,
fusion proteins of the invention exert much stronger effect compared to
rhTRAILI 14-281 alone.
Mice cId Hrhr
A. On day 0 mice Crt:SHO-PrkdCscid hr were grafted subcutaneously
(Sc) in the
right side with 5x10 6 of HepG2 cells suspended in 0.2 ml HBSS buffer by means of
a syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
- 19 0-220 mm (day 31), mice Were randomized to obtain the average size of
tumors In the group of - 200 mm’ and assigned to treatment groups. The
ent groups were administered with the preparations of fusion protein of
the ion of Ex; 6 (30 , Ex.19 (30 mg/kg) and rhTRAILII4-281 (30
mg/kg) as a comparison against formulation buffer (5 mM NaH2PO4, 95 mM
Na2HPO4, 200 MM NaCl, 5 mM glutatione, 0,1 mM ZnCl2, 10% glycerol, 80 MM
saccharose, pH 8.0) as a control. The preparations were administered
intravenously (i.v.) six times every second day. When a eutic group
reached the average tumor size of - 1000 mm 3, mice were sacrificed by
tion of the spinal cord. The control group received rhTRAILII4-281.
The experimental results obtained in mice - PrkdcHr burdened with
HepG2 Liver cancer treated with fusion proteins of the invention of Ex. 6, Ex. 1
and comparatively with rhTRAILII4-281 are shown in Fig. 30 as a diagram of
changes of the tumor volume and in Fig. 31 which shows tumor growth inhibition
(%TGI) as the percentage of control.
10 On day 0 mice Crl:SHO.PrkdcidHr were grafted subcutaneously (Sc) in the right
side with 7x106 of PANC1 cells ded in 0.1 ml of HBSS:MatrigeL 3:1 mixture
by means of a syringe with a 0.5 x25 mm needle (Bogmark). When tumors
reached the size of - 87-110mm 3 (day 27), mice were randomized to obtain the
average size of tumors in the group of - 95 mm 3 and assigned to treatment
groups. The treatment groups were administered with the preparation of fusion
protein of the ion of Ex. 11 (50 mg/kg) and rhTRAILI 14-281 (20 mg/kg) as
a comparison against formulation buffer (5 MM NaH 2PO4, 95 mM Na2HPO 4, 200
mM NaCl, 5 MM glutation, 0.1 mM ZnCL 2, 100 mM L-arginine, 80 mM saccharose,
pH 8.0) as a control. The preparations were administered intravenously (I V.) six
times every second day. When a therapeutic group reached the average tumor
size of - 1000 mm 3, mice were sacrificed by disruption of the spinal cord. The
control group received rhTRAILI14-281.
The experimental s obtained in mice CrE:SHO.PrkdciHrh1r burdened with
PANCI pancreas cancer treated with fusion n of the invention of Ex. I land
25 comparatively with rhTRAILI14-281 are shown in Fig. 32 as a diagram of changes
of the tumor volume and in Fig. 33 which shows tumor growth inhibition (%TGI)
as the percentage of control.
The results of ments presented in the graphs in Figures 32 and 33 show
that stration of the fusion protein of the invention Ex. 11 caused tumor .
PANC1 growth inhibition, with TGI 43% relative to the control on 40" day of the
experiment. For rhTRAILII4-281 used as the comparative reference, the slight
tory effect on tumor cell growth was obtained relative to the control, with
TGI at the Level o 12.0%. Thus, fusion proteins of the invention exert much
stronger effect compared to rhTRAIL1I4-281 atone.
Muttidrug-resistant human uterine sarcoma model On day 0 mice Crl:SHOPrkdcsH
rt were grafted subcutaneously (Sc) ifl the nght side with 7x10 6 of MES
SA/Dx5 cells suspended in 0 1 ml of HBSSMatngel 10 1 e by means of a
syringe with a 0.5 x25 mm needle (Bogmark). When tumors reached the size of
167-190 mm (day 19), mice were randomized to obtain the average size of
tumors in the group of - 180 mm 3 and assigned to treatment groups. The
treatment groups were administered with the preparations of fusion proteins of
the invention of Ex. 6 , Ex. 19 (30 mg/kg) and rhTRAILII4-281 (10 mg/kg) as a
comparison t formulation buffer (5 mM NaH2PO4, 95 mM Na2HPO4, 200 mM
NaCl, 5 mM glutatione, 0.1 mM ZnCl2, 10% glycerol, 80 mM saccharose, pH 8.0) as
a control. The preparations were administered enously (i.v.) six times
every second day. When a therapeutic group reached the average tumor size of
- 1000 mm 3, mice were sacrificed by tion of the spinal cord. The control
group received rhTRAILII4-281.
sdd Hr-hr
The experimental results obtained in mice Crl-SHO-PrkdC burdened with
/Dx5 uterine sarcoma treated with fusion proteins of the invention of Ex.
18, Ex 6 , Ex 19 and comparatively with rhTR4I1.II4481 are shown in Fig 34 as
a diagram of changes of the tumor volume and in Fig 35 which shows tumor
growth inhibition (%TGI) as the percentage of control
The results of experiments presented in the graphs in s 34 and 35 show
that administration of the fusion proteins of the invention Ex. 6 , Ex. 19 caused
tumor MES-SA/Dx5 growth inhibition, with TGI tively 99.7% and 99.7%
relative to the control on 33 t day of the experiment. For rhTRAILII4-281 used
as the comparative nce, the slight inhibitory effect on tumor cell growth
was ed relative to the control, with TGI at the level of 29%. Thus, fusion
proteins of the invention exert much stronger effect compared to rhTRAILII4-
281 alone.
Claims (19)
1 A fusion protein comprising - domain (a) comprising a functional fragment of soluble hTRAIL protein sequence starting with amino acid in a position not lower than hTRAIL95 Or a sequence having at least 70% sequence identity with said functional fragment; and - domain (b) constituting a sequence of ngiogenic or peptide which is the inhibitor of growth factor receptor and is selected from the group of growth factor fragments consisting of VEGF fragment of SEQ. No. 17, PDGF fragment of SEQ. No. 22 and EGF fragment of SEQ. No. 23; n the sequence of domain (b) is attached at C - us or N - terminus of domain (a).
2. A fusion protein according to claim 1, wherein domain (a) comprises a the fragment of soluble hTRAIL protein sequence starting with an amino acid from the range hTRAIL95 to hTRAIL121, inclusive, and ending with the amino acid hTRAIL 281.
3. A fusion protein according to claim 1 or 2, wherein domain (a) is selected form the group consisting of hTRAIL95-281, hTRA[L1 19-281, hTRAIL120-281 and hTRAIL12I-281.
4. A fusion protein according to any of the claims 1 to 3, wherein the fusion protein between the domain (a) and domain (b) contains domain (c) comprising a protease cleavage site, selected from a ce recognized by metalloprotease MMP, a sequence recognized by urokinase uPA, and combinations thereof.
5. A fusion protein according to claim 4, n the sequence recognized by metalloprotease MMP is SEQ. No. 24, SEQ. No. 55 or SEQ. No.56, the sequence recognized by urokinase uPA is SEQ. No. 25.
6. A fusion protein according to claims 4 or 5, wherein domain (c) is a ation of ces recognized by metalloprotease MMP and urokinase uPA located next to each other. 8457768
7. A fusion protein according to any of the preceding claims, wherein the protein between domains (a), (b) and/or (c) comprises additionally glycine, glycine-serine or cysteine le steric linker or combinations f
8. A fusion protein according to claim 7, wherein flexible steric linker is ed from the group consisting of GO, B, 000CAAACAAC (SEQ. No. 26), GGCAAACAAC (SEQ. No. 27), GGGGG (SEQ. No. 28), GGGG (SEQ. No. 29), GGG (SEQ. No. 30) and GSG (SEQ. No. 54).
9. A fusion protein according to claim 1, consisting of the amino acid sequence ponding to the sequence selected form the group consisting of SEQ. No.!; SEQ. No.2; SEQ. No.3; SEQ. No.4; SEQ. No.5; SEQ. No.6; SEQ. No.9; SEQ. No.10; SEQ. No. 11; SEQ. No. 14; SEQ. No. 15; SEQ. No.46; No.47; SEQ. No.48, and SEQ. No.49.
10. A fusion protein according to any of the preceding claims, which is a recombinant protein.
11. An ed polynucleotide sequence, coding the fusion protein defined as in any preceding claims 1 to 9.
12. The sequence ing to claim 11, optimized for genetic expression in E. coli.
13. A sequence according to claim 12, selected from the group consisting of SEQ. No.3 1; SEQ. No.32; SEQ. No.33; SEQ. No.34; SEQ. No.35; SEQ. No.36; SEQ. No.39; SEQ. No.40; SEQ. No.41; SEQ. No.44; SEQ. No.45; SEQ. No.50; SEQ. No.51; SEQ. No.52, and SEQ. No.53.
14. An expression vector, sing polynucleotide sequence according to any of the claims 11 to 13.
15. A host cell, comprising the expression vector as defined in claim 14, wherein the host cell is not within a human body.
16. A host cell according to claim 15, which is a E. coli cell.
17. A pharmaceutical composition, comprising as an active ingredient the fusion protein as defined in any of the preceding claims I to 10, in combination with any pharmaceutically acceptable carrier. 8457768
'18.. A pharmaceutical comfiosition according to claim 17‘, in a form ”for paiente'ralsi ' administration.
19. Use of ‘a fusion protein :as defined many of the preCedin'g claims I to 10 ‘for' the I. :fiianiifact'ufé of a medicament " H ' 'fdi‘ "the 'trééfifient ‘O'f'hébfilléé‘tic- diseases in mmmfill-SUJMW including humans.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PLPL393578 | 2011-01-05 | ||
PL393578A PL219845B1 (en) | 2011-01-05 | 2011-01-05 | Anticancer fusion protein |
PCT/EP2012/050145 WO2012093158A1 (en) | 2011-01-05 | 2012-01-05 | Anticancer fusion protein |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ609219A NZ609219A (en) | 2014-06-27 |
NZ609219B2 true NZ609219B2 (en) | 2014-09-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2661496B1 (en) | Anticancer fusion protein | |
CA2800841C (en) | Anticancer htrail/pre-apoptotic effector fusion proteins | |
US9161991B2 (en) | Anticancer fusion protein comprising TRAIL and interferon | |
US20150044162A1 (en) | Anticancer fusion protein | |
BR112014015922A2 (en) | anticancer fusion protein | |
US20140031283A1 (en) | Anticancer fusion protein | |
NZ609219B2 (en) | Anticancer fusion protein |